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ABSTRACT 
Kynurenic acid, a metabolite of tryptophan along the kynurenine pathway, is an endogenous 
antagonist at NMDA- and α7* nicotinic acetylcholine- (α7*nACh) receptors. Previous studies 
have shown that elevated levels of endogenous kynurenic acid are associated with an increased 
firing of midbrain dopamine neurons as well as a reduced prepulse inhibition (PPI), a 
behavioral model for sensorimotor gating. Furthermore, kynurenic acid is elevated in the CSF 
and in the postmortem prefrontal cortex of patients with schizophrenia. The aim of this thesis 
was to investigate the mechanisms of action of kynurenic acid with regard to its action on 
midbrain dopamine firing and PPI; to analyze the interaction between the antipsychotic drug 
clozapine and kynurenic acid, and finally; to further study the involvement of kynurenic acid in 
psychiatric disorders.  
 The excitation of ventral tegmental area (VTA) dopamine neurons observed in rats with 
elevated levels of kynurenic acid were mimicked by pretreatment with 4-chlorokynurenine (4-
Cl-KYN). Administration of SDZ 220-581 was also found to increase firing of VTA dopamine 
neurons. However, administration of methyllycaconitine (MLA) decreased firing of these 
neurons. These results demonstrate that the increased firing of VTA dopamine neurons 
following elevation of brain kynurenic acid is primarily mediated through glutamatergic rather 
than by cholinergic mechanisms. 
 Administration of SDZ 220–581 or CGS 19755 was associated with a robust reduction in 
PPI, whereas L-701,324, 4-Cl-KYN or MLA failed to alter PPI. Kynurenine increased brain 
kynurenic acid levels 5-fold and tended to decrease PPI. These results suggest that neither 
antagonism of the glycine site of the NMDA receptor nor antagonism of the α7*nACh receptor 
disrupts PPI. Rather, blockade of the glutamate recognition site is necessary to reduce PPI. 
 Clozapine increased firing of VTA dopamine neurons in control rats. Pretreatment with 
indomethacin was found to elevate brain kynurenic acid levels and to reverse the excitatory 
action of clozapine into an inhibitory response. In contrast, pretreatment with parecoxib 
decreased brain kynurenic acid formation and clearly potentiated the excitatory effect of 
clozapine. These results show that endogenous levels of brain kynurenic acid are of importance 
for the response of clozapine on VTA dopamine neurons and we propose that clozapine is able 
to interact as a partial agonist with the glycine site of the NMDA receptor. 
 CSF kynurenic acid and kynurenine was found to be elevated in patients with 
schizophrenia compared to controls. Violent male suicide attempters and male suicide 
attempters with a diagnosis of major depression had higher CSF kynurenic acid than controls. 
Furthermore, CSF levels of kynurenic acid correlated with CSF MIP-1β in all subjects, with 
CSF eotaxin-3 in controls and tended to correlate with IL-6 in all subjects.  
 An up-regulated kynurenine pathway may be a consequence of an activated immune 
system as studies have shown that immunological agents induce the first and rate-limiting 
enzymes in the production of kynurenic acid, thus indicating that kynurenic acid is a marker of 
immune-activation. Elevation of endogenous kynurenic acid may be a potential mechanism by 
which the immune system initiate psychiatric symptoms. This theory is supported by the close 
correlation between cytokines/chemokines and kynurenic acid in the CSF of suicide attempters 
observed in the present thesis. Altogether the present results suggest that kynurenic acid, with 
its unique receptor profile, may be the link between an activated immune system and the 
alterations in glutamatergic, cholinergic and dopaminergic neurotransmission proposed to occur 
in psychiatric disorders.  
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1 INTRODUCTION 
 
1.1  Schizophrenia 
Schizophrenia is a severe mental illness characterized by abnormalities in perception or 
expression of reality. The disorder has a major impact on social functioning and is 
almost always of a chronic character. The global prevalence is approximately 0.55 to 
0.85% (Carpenter and Buchanan, 1994; Goldner et al., 2002). The onset of symptoms 
typically occurs in young adulthood and usually occurs a few years earlier in men than 
in women. Average life expectancy of people with schizophrenia is 10 to 12 years less 
than those without (Brown et al, 2000). This is due to increased physical health 
problems and a higher suicide rate, accounting for approximately 5-10% of the deaths 
in patients with the disorder (Black and Fisher, 1992; Meltzer et al., 2002; Palmer et al., 
2005). Patients with schizophrenia also have an increased risk for psychiatric 
comorbidity, including major depressive disorder (MDD), anxiety disorders and 
substance abuse (Sim et al., 2006). As a result, schizophrenia is not only associated 
with substantial human suffering, but also with high costs to society in terms of 
healthcare and loss in productivity. 
 
Symptoms of schizophrenia most commonly manifest as hallucinations, delusions or 
disorganized speech and thinking. There is also often an observable pattern of 
emotional difficulties as well as impairment in social cognition leading to isolation and 
social withdrawal, although the individual expression of symptoms may vary. To guide 
clinicians and investigators the symptoms are often divided into three broad clusters: 
positive symptoms, negative symptoms and cognitive impairments (Andreasen, 1995). 
Positive symptoms refer to symptoms that most individuals do not normally 
experience, such as paranoid or bizarre delusions, auditory hallucinations and thought 
disorder. These are typically regarded as manifestations of psychosis. Negative 
symptoms reflect absence or loss of abilities normally found in healthy persons. 
Common negative symptoms include blunted affect and emotion, anhedonia, poverty of 
speech (alogia), lack of motivation and asociality. Cognitive impairments seen in 
patients with schizophrenia include deficits in memory, attention and executive 
functions, lack of judgment and insight. The positive (psychotic) symptoms tend to be 
episodic over time, often necessitating temporary hospitalization. In contrast, negative 
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symptoms and cognitive impairments tend to be more stable but are suggested to 
contribute more to functional impairment and disability as well as poor quality of life 
(Fenton and McGlashan, 1991; Green et al., 2000).  
 
The causes of schizophrenia have been the subject of much debate and the complexity 
of the disorder has made the search for a pathophysiological explanation extremely 
difficult. Family, twin and adoption studies provide evidence indicating genetic factors 
contributing to the disease. Thus, the risk among first-degree relatives is approximately 
10-fold higher than in the general population and adoption studies indicate an increased 
risk in those with a biological parent with schizophrenia (Kessler, 1980; McGue and 
Gottesman, 1991; Harrison and Owen, 2003). Despite studies reporting concordance 
rates between monozygotic twins as high as 50 – 84% (Farmer et al., 1987; Cardno et 
al., 1999), the lack of complete concordance indicates that neurodevelopmental and 
environmental factors also contribute to the cause of the disease. Thus, it has been 
suggested that the primary pathological process of schizophrenia occurs during brain 
development, e.g. by obstetric complications, maternal stress, malnutrition or smoking 
during pregnancy (Mortensen et al., 1999; Susser and Lin, 1992). Furthermore, 
environmental factors associated with schizophrenia include psychosocial factors such 
as urban upbringing, social isolation, migration and drug abuse (Susser, 2002). Recent 
epidemiological studies suggest that an immunological component may play a part in 
the etiology as well (Sperner-Unterweger, 2005). For instance, prenatal infections 
during the second trimester are associated with an increased risk of schizophrenia 
(Brown, 2006). In support of an immunological component in schizophrenia, we 
recently reported that the pro-inflammatory cytokine interleukin (IL)-1β is markedly 
elevated in the CSF of first-episode patients with schizophrenia (Söderlund et al., 
2009). 
 
1.1.1 Antipsychotic drugs, clozapine 
Schizophrenia is associated with positive, negative and cognitive symptoms (see 1.1). 
The beneficial effects of classic antipsychotic drugs (e.g. haloperidol) in ameliorating 
the positive symptoms of schizophrenia are thought to be related to a reduced 
dopaminergic neurotransmission within the limbic region of the brain (Carlsson et al, 
2001). However, reduced dopaminergic neurotransmission is also associated with 
severe side effects, such as extrapyramidal side effects (EPS; Farde et al., 1992; 
Klas Linderholm 
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Gerlach, 2002). The antipsychotic drug clozapine has very low incidence of EPS and 
has thus been classified as an atypical antipsychotic drug (Claghorn et al., 1987; 
Coward et al., 1989). Furthermore, clozapine has a superior efficacy in treatment-
resistant schizophrenia as well as in ameliorating negative symptoms (Hagger et al., 
1993; Breier et al., 1994) and cognitive deficits (Kane et al., 1988). Clozapine is 
therefore considered the most effective antipsychotic drug used today (Kane et al., 
1988; Pickar et al., 1992). The efficacy is suggested to be related to a relatively weak 
binding potential to dopamine D2 receptors (Kapur and Seeman, 2001) and/or to a 
preferential action on the mesolimbic dopamine system (Anden and Stock, 1973; 
Bartholini, 1976; Chiodo and Bunney, 1983; 1985; Moghaddam and Bunney, 1990). 
Moreover, it is established that clozapine not only interacts with a variety of dopamine 
receptors, but also with receptors for serotonin (5-HT; Meltzer and Huang, 2008), 
acetylcholine (Snyder et al., 1974; Bymaster et al., 2003), noradrenaline (Coward, 
1992) and histamine (Brunello et al., 1995; Coward, 1992). Studies also show 
interaction with the N-methyl-D-aspartate (NMDA) receptor (Arvanov et al., 1997; 
Lidsky et al., 1993; Ninan and Wang, 2003; Ossowska et al., 1999; Jardemark et al., 
2003, Schwieler and Erhardt, 2003, Schwieler et al., 2004) and the γ-aminobutyric 
acidA (GABAA) receptor (Squires and Saederup, 1998). Unfortunately, clozapine is 
associated with a risk of severe side effects, especially potentially fatal agranulocytosis 
(Idänpään-Heikkilä et al., 1977; Krupp and Barns, 1992). Nevertheless, the superiority 
of clozapine as an antipsychotic drug has led to the development of a new generation of 
antipsychotic drugs, e.g. olanzapine, risperidone, quetiapine and ziprasidone, nowadays 
widely used in the treatment of schizophrenia.  However, also these newly developed 
drugs are associated with side effects, most prominently weight gain and altered 
glucose and lipid metabolism, resulting in increased risk of cardiovascular diseases 
(Gardner et al., 2005). Thus, the need for novel, more effective and tolerable drugs in 
the treatment of schizophrenia is substantial.  
 
1.2  Hypotheses of schizophrenia 
The field of schizophrenia research has shifted dramatically over the years. Today most 
evidence indicates that the pathophysiological processes leading to the development of 
schizophrenia are related to alterations in several neurotransmitters, especially 
dopamine and glutamate (Javitt and Zukin, 1991; Jentsch and Roth, 1999; Carlsson et 
al., 2001; Javitt, 2007).  
Introduction 
 
 13 
1.2.1  The dopamine hypothesis of schizophrenia 
The dopamine hypothesis originally proposed a hyperactivity of the dopamine system 
as the underlying cause of psychotic symptoms in patients with schizophrenia (Carlsson 
and Lindqvist, 1963). For several decades this was the predominant theory and 
originated from findings that antipsychotic drugs reverse the symptoms (by blocking D2 
receptors) and that dopamine-releasing drugs (e.g. amphetamine) can induce a state of 
psychosis (Snyder, 1973; Angrist and van Kammen, 1984, Carlsson et al., 2001). The 
first compound to be used in the treatment of schizophrenia was chlorpromazine (Delay 
and Denicker, 1952) and since then several antipsychotic drugs have been developed 
with the common feature of antagonizing the dopamine D2 receptor. However, over the 
years more attention has been focused on the negative and cognitive symptoms and the 
resistance they show to dopamine D2 receptor antagonists (King, 1998; Breier, 1999). 
These symptoms have been suggested to be caused by persistent deficits in dopamine 
transmission at dopamine D1 receptors in the prefrontal cortex, whereas an excess of 
subcortical dopamine functions, involving activation of dopamine D2 receptors, 
contribute to the positive symptoms (Davis et al., 1991; Jentsch and Roth, 1999; Abi-
Dargham and Laurelle, 2005). These findings have led to a reformulation of the 
original dopamine hypothesis to a dopamine imbalance theory of schizophrenia (Abi-
Dargham and Laurelle, 2005). Thus, simultaneous occurrence of both both hypo- and 
hyperdopaminergic states is nowadays generally accepted as a theory for the cause of 
the symptoms. In recent years, data from brain imaging studies have provided further 
support for an abnormal dopamine activity in patients with schizophrenia. Studies have 
shown increased baseline dopamine release during phases of exacerbation of psychosis, 
and an increased release of dopamine after amphetamine administration, in patients 
with schizophrenia compared to control subjects (Abi-Dargham et al., 1998; 2000; 
Laruelle et al., 1996; Breier et al, 1997; Abi-Dargham and Laruelle, 2005). The 
dopamine imbalance theory for schizophrenia is also supported by studies showing 
reduced central dopamine output in chronic patients (Karoum et al., 1987). However, 
the underlying mechanisms behind such an imbalance in the dopamine systems remains 
to be revealed. 
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1.2.2  The glutamate deficiency theory of schizophrenia 
About half a century ago, clinical observations of symptoms indistinguishable from 
schizophrenia were made following administration of a dissociative anaesthetic (Luby 
et al., 1959; Itil et al., 1967). The drug used, phencyclidine (PCP), was developed and 
introduced as an “ideal” anaesthetic, but was later found to be associated with severe 
side effects, e.g. hallucinations, paranoia, delusions and disorganized speech during 
anaesthetic recovery (Pradhan, 1984). Furthermore, a significant number of patients 
developed psychosis, which persisted long after the recovery from anaesthesia, and 
consequently the drug was withdrawn from the market and human use in 1965 
(Pradhan, 1984; Domino and Luby, 1981). Over a decade later, it was found that in 
subanaesthetic doses (0.05-0.1 mg/kg) PCP acts as a non-competitive NMDA receptor 
antagonist (Zukin and Zukin, 1979; Vincent et al., 1979). The glutamate deficiency 
theory of schizophrenia was hence formulated, based on these findings together with a 
report showing low levels of glutamate in the CSF of patients with schizophrenia (Kim 
et al., 1980). Furthermore, several studies have also revealed that other non-competitive 
NMDA receptor antagonists, e.g. ketamine, exacerbate both positive and negative 
symptoms in patients with schizophrenia (Luby et al., 1959; Itil et al., 1967; Malhotra 
et al., 1997; Jentsch and Roth, 1999). Also, these compounds can induce cognitive 
dysfunctions as well as positive and negative symptoms of schizophrenia in healthy 
controls (Javitt and Zukin, 1991; Krystal et al., 1994; Tamminga, 1998; Jentsch and 
Roth, 1999). Hereby, PCP-induced psychosis in healthy volunteers is indistinguishable 
from an acute episode of schizophrenia (Yesavage and Freman, 1978; Erard et al., 
1980). When further investigated, it was found that not only non-competitive NMDA 
receptor antagonists, but also competitive NMDA receptor antagonists as well as 
antagonists of the glycine site of the NMDA receptor are able to induce symptoms of 
schizophrenia (Kristensen et al., 1992; Grotta et al., 1995; Yenari et al., 1998; Albers et 
al., 1999). Furthermore, adjunctive treatment with glycine or D-serine shows beneficial 
effects on schizophrenia, particularly with regard to negative symptoms, indirectly 
supporting the glutamate deficiency theory (Tuominen, 2005). 
 
In electrophysiological experiments, systemic administration of NMDA receptor 
antagonists in rats is associated with an increase in firing rate and burst firing activity of 
midbrain dopamine neurons (French et al., 1993; French, 1994; Erhardt et al., 2001; 
Erhardt and Engberg, 2002; Schwieler et al, 2004). This paradoxical activation is 
Introduction 
 
 15 
suggested to be caused by an inhibition of tonic GABAergic input to the midbrain 
dopamine neurons (Zhang et al., 1993). Furthermore, studies show that subchronic 
administration of PCP to rats not only increases dopamine release in mesolimbic areas, 
i.e. the nucleus accumbens (Jentsch et al., 1998; Jentsch and Roth, 1999), but also 
reduces dopamine release in the prefrontal cortex (Jentsch et al., 1997; 1998a; b). As 
previously mentioned (see 1.2.1), hypofunction in the prefrontal dopamine system has 
been suggested to result in negative and cognitive symptoms (Weinberger et al., 1988; 
Daniel et al., 1989; 1991; Dolan et al., 1995). Thus, chronic PCP administration is 
suggested to produce effects most consistent with schizophrenia, mimicking both 
dopaminergic hypofunction in the prefrontal cortex as well as a hyperdopaminergic 
state in the nucleus accumbens (Jentsch and Roth, 1999). Altogether, increasing 
evidence suggests that an altered dopamine function in schizophrenia may be a 
consequence of NMDA receptor hypofunction, although the reason for such a 
deficiency remains to be determined.  
 
1.2.3 The kynurenic acid hypothesis of schizophrenia 
In the early 2000s it was discovered that patients with schizophrenia display elevated 
levels of kynurenic acid in the cerebrospinal fluid (CSF; Erhardt et al., 2001a) and in 
the prefrontal cortex in postmortem patients (Schwarcz et al., 2001). These findings 
were later confirmed in a large cohort of patients with schizophrenia, including both 
drug-naïve, first-episode patients as well as patients on antipsychotic treatment (Nilsson 
et al., 2005). In line with higher concentrations of kynurenic acid in the post mortem 
brain of patients with schizophrenia, it has been shown that the levels of kynurenine are 
also elevated in the post mortem brain of these patients (Miller et al., 2006; 2008). 
Elevated kynurenine and kynurenic acid levels in patients with schizophrenia may arise 
from an increased synthesis of kynurenine from tryptophan, or alternatively, a 
decreased synthesis of 3-hydroxykynurenine from kynurenine. An increased synthesis 
of kynurenine might result from an induction of tryptophan-2,3-dioxygenase (TDO) 
and/or indoleamine-2,3-dioxygenase (IDO), enzymes known to be induced during 
infections or immune-activation (Holtze et al., 2008; Asp et al., 2009; Schmidt et al., 
2009) and numerous studies suggest that kynurenic acid is a biological marker of 
neuroinflammation (King and Thomas 2007; Dantzer et al., 2008). Supporting an 
activation of the brain immune system in schizophrenia, it was recently found that the 
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CSF concentration of the pro-inflammatory cytokine IL-1β is elevated in first-episode 
patients (Söderlund et al., 2009). Indeed, gene expression of TDO as well as the density 
of TDO-immunopositive cells is found to be elevated in post mortem brain of patients 
with schizophrenia, whereas IDO expression appears to be unaffected (Miller et al., 
2004; 2006). A decreased synthesis of 3-hydroxykynurenine from kynurenine, resulting 
in increased kynurenine levels, is supported by experimental as well as genetic studies. 
It is well known that pharmacological blockade of the enzyme converting kynurenine 
to 3-hydroxykynurenine, kynurenine 3-monooxygenase (KMO), results in elevated 
brain kynurenic acid levels (Erhardt et al., 2009). In addition, we recently reported that 
a non-synonymous polymorphism in the KMO gene results in higher CSF kynurenic 
acid levels in both healthy volunteers and patients with schizophrenia (Holtze et al., 
2010). Also, a post mortem study shows decreased KMO gene expression as well as 
decreased KMO enzyme activity in individuals with schizophrenia (Sathyasaikumar et 
al., 2009).  
 
The unique properties of kynurenic acid, i.e. being an antagonist of both NMDA 
receptors and the α7*nicotinic acetylcholine receptor (α7*nACh), is particularly 
interesting given that hypoglutamatergia, possibly induced by NMDA receptor 
hypofunction, is widely accepted as part of the pathophysiology of schizophrenia (Javitt 
et al., 2007). In addition, the importance of intact α7*nACh receptor signaling in 
cognitive functions has been suggested in numerous studies during the last decade 
(Albuquerque et al., 2009). In further support of the kynurenic acid hypothesis of 
schizophrenia, animal studies show that pharmacologically elevated levels of brain 
kynurenic acid impair contextual learning and working memory (Chess and Bucci 
2006; Chess et al., 2007; 2009) and disrupt prepulse inhibition (PPI; Erhardt et al., 
2004), a behavioral model measuring sensory motor gating, domains well-known to be 
affected in patients with schizophrenia. Furthermore, rats with acutely as well as 
subchronically elevated levels of kynurenic acid in the brain display increased midbrain 
dopamine firing activity, mimicking the effect seen following administration of 
psychotomimetic NMDA receptors antagonists (Erhardt and Engberg, 2002; Erhardt et 
al., 2003; Nilsson et al., 2006; French et al., 1993; 1994). Indeed, midbrain dopamine 
neurons are suggested to play an important role in generating positive symptoms in 
schizophrenia, where an increased phasic release of dopamine (Grace, 1991) induced 
by burst-firing activity of these neurons, may mediate the excess of subcortical 
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dopamine (Davis et al., 1991; Jentsch and Roth 1999). Therefore, the increased firing 
of rat midbrain dopamine neurons following chronically elevated levels of kynurenic 
acid (Nilsson et al., 2006; Olsson et al., 2009) may represent a pathophysiological 
condition similar to that seen in patients with schizophrenia. Indeed, in rats with 
subchronically elevated levels of KYNA, dopamine release in the nucleus accumbens is 
clearly enhanced following an amphetamine challenge (Olsson et al., 2009), a finding 
in agreement with the increased striatal dopamine release by amphetamine, as observed 
by brain imaging studies in patients with schizophrenia (Laruelle et al., 1999).  
 
Interestingly, cyclo-oxygenase (COX)-2 inhibitors, e.g. celecoxib and parecoxib, which 
decrease rat brain kynurenic acid concentration and dopaminergic activity (Schwieler et 
al. 2005; 2006), display beneficial antipsychotic effects when added to conventional 
antipsychotic treatment in patients with schizophrenia (Müller et al. 2002). In contrast, 
COX-1 inhibitors, e.g. diclofenac and indomethacin, are associated with an increase in 
brain kynurenic acid concentration and subsequent increase in dopaminergic activity 
(Schwieler et al. 2005; 2006), and such drugs have been reported to induce psychotic 
side effects (see Hoppmann et al. 1991; Tharumaratnam et al. 2000; Clunie et al. 2003).  
 
1.3 Suicide 
Suicide accounts for approximately one million deaths annually worldwide and the 
frequency of suicide attempts is approximately 20 times that of completed suicides 
(WHO). The rates of suicide have increased by 60% in the past half century, mainly in 
developing countries (WHO). The prevalence varies between countries but the highest 
rates are found in Asia and Eastern and Northern Europe, including Sweden (WHO). 
However in some regions the reported number of suicides might be extraordinary low 
due to social, religious and political factors and demonstrate the stigmatization and 
taboo suicide is associated with. In Sweden, as well as in many other countries, suicide 
is the leading cause of death between the ages 15 and 44, whereas most suicides are 
committed by people over the age of 45 (NASP). Men are more likely to commit 
suicide but women attempt suicide three times as often (WHO; NASP). Studies show 
an incidence of mental disorder between 80 and 98% in all suicide victims and suicide 
attempters, most commonly mood disorders, followed by substance abuse and 
schizophrenia (Arsenault-Lapierre et al, 2004; Bertolote et al, 2004). MDD is the most 
prevalent psychiatric diagnosis among suicide victims as well as attempters. 
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Schizophrenia is the third most common psychiatric disorder in suicide victims and 
suicide accounts for approximately 5-10% of all deaths in this patient category (see 1.1; 
Black and Fisher, 1992; Palmer et al., 2005). 
 
1.3.1  Immunological aspects 
In many ways depressive symptoms resemble ”sickness behavior”, i.e. fatigue, 
anorexia, loss of interest in social activities, failure to concentrate, anhedonia and 
exacerbation of symptoms by stressors (Charlton, 2000). Interestingly, sickness 
behavior is induced by pro-inflammatory cytokines as an inflammatory response of the 
immune system (Charlton, 2000). Already in the early 1990s it was suggested that the 
immune system could be involved in depressive disorders (Smith, 1991). Since then the 
field of psychoneuroimmunology has grown enormously and our knowledge on the 
immune-to-brain communication and the interference between the central nervous 
system (CNS) and the immune system has increased. Indeed, the potential role of 
immune mediators in psychiatric disease has recently become widely recognized 
(Dantzer et al, 2008). Several studies show increased blood levels of pro-inflammatory 
cytokines in depressed patients, e.g. interleukin-6 (IL-6; Berk et al., 1997), IL-1β 
(Thomas et al., 2005) and tumor necrosis factor-α (TNF-α; Hestad et al., 2003; Mikova 
et al., 2001), as well as in suicide attempters (Mendlovic et al., 1999; Kim et al., 2008). 
In line with this notion, it is shown that immunotherapy with cytokines, e.g. interferon-
γ, induces depressive symptoms approximately one month after start of medication 
(Raison et al., 2009; Wichers and Maes 2004; Wichers et al., 2005). Correspondingly, 
the symptoms are well-treated with antidepressant drugs (Capuron et al, 2002). 
Furthermore, current antidepressant drugs may alleviate symptoms of depression via 
anti-inflammatory actions (Kulmatycki and Jamali, 2006), and a small-scale study 
using COX-2 inhibitors has demonstrated positive results in treatment-resistant 
depression (Müller et al 2006). However, there is presently very limited knowledge 
about the details of the interactions between neurobiological and immunological 
factors, and the link to specific psychiatric symptoms. However recently, it was shown 
that CSF IL-6 is higher in individuals with MDD that had made a suicide attempt than 
in healthy volunteers. Patients who performed violent suicide attempts displayed the 
highest levels of IL-6, and IL-6 correlated positively with the severity of depressive 
symptoms (Lindqvist et al., 2009). 
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1.4  The kynurenine pathway 
Kynurenic acid was first identified 1853 in canine urine (Liebig, 1853). Following the 
discovery of tryptophan (Hopkins and Cole, 1901), an amino acid required by all life 
forms for protein synthesis, the compound was recognized as a tryptophan metabolite 
(Ellinger, 1904). Later on, the sequence of enzymatic steps converting tryptophan to 
kynurenines, including kynurenic acid, was named the ”kynurenine pathway” (Beadle 
et al., 1947; fig. 1). This pathway produces three neuroactive metabolites, i.e. kynurenic 
acid, an anticonvulsant and neuroprotectant, quinolinic acid, an excitotoxin, and 3-
hydroxykynurenine, a free-radical generator (Stone et al., 1993). Of these compounds, 
kynurenic acid and quinolinic acid are suggested to participate in brain physiological 
and pathophysiological processes (Erhardt et al., 2009; Chen and Guillemin, 2009).  
 
In mammals, the 
kynurenine pathway 
metabolizes over 95% of 
all dietary tryptophan 
(Wolf, 1974; fig. 1) 
whereas only a minor 
fraction is metabolized to 
the neurotransmitter 
serotonin (Peters, 1991). 
The first and regulatory 
step in the pathway is 
controlled by the two 
enzymes TDO (Hayaishi 
et al., 1993) and IDO 
(Hayaishi, 1976), both 
inducing the oxidative 
opening of the indole ring 
of tryptophan. The 
product, formyl 
kynurenine, is rapidly converted to the key metabolite L-kynurenine by kynurenine 
formylase (Mehler and Knox, 1950; Gál and Sherman, 1978). Kynurenine serves as 
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substrate for three different enzymes: I) kynureninase, which forms anthranilic acid, II) 
kynurenine 3-hydroxylase, which forms 3-hydroxy-kynurenine, and III) kynurenine 
aminotransferase (KAT), which forms kynurenic acid (Moroni, 1999). The enzymes of 
the kynurenine pathway in the brain are primarily expressed in astrocytes, microglial 
cells and infiltrating macrophages (Okuno et al., 1991b; Du et al., 1992; Heyes et al., 
1996; Guillemin et al., 2001; Kiss et al., 2003; Miller et al., 2004). However, 
degradation of kynurenine seems to be spatially separated as the enzymes responsible 
for the synthesis of kynurenic acid or quinolinic acid are mainly expressed in astrocytes 
or microglia, respectively. Astrocytes appear to preferentially synthesize kynurenic 
acid, as they contain very little kynurenine 3-hydroxylase, whereas microglia favor the 
formation of quinolinic acid due to their very low expression of KAT (Guillemin et al., 
2001; Kiss et al., 2003; Lehrmann et al., 2001). In fact, astrocytes seem more capable 
of degrading quinolinic acid than producing the compound (Guillemin et al., 2001). 
Under normal conditions, it is suggested that most kynurenine is metabolized by 
kynurenine 3-hydroxylase, having the highest enzymatic affinity to kynurenine (Bender 
and McCreanor, 1982; Moroni, 1999). Subsequently, anthranilic acid and 3-
hydroxykynurenine can be metabolized to 3-hydroxyanthranilic acid and then to the 
neurotoxic compound quinolinic acid (Stone and Perkins, 1981). Further metabolism 
along this branch of the kynurenine pathway results in either total oxidation (generating 
adenosine triphosphate and CO2) or synthesis of nicotinamide adenine dinucleotide 
(NAD+;  Hayaishi, 1993).  
 
1.4.1   Kynurenic acid 
In 1988, two independent research groups discovered the presence of kynurenic acid in 
the human brain (Moroni et al., 1988; Turski et al., 1988). In line with this finding, it 
was later discovered that all enzymes required for the formation of kynurenic acid from 
tryptophan are present in the brain (Swartz et al., 1990; Guidetti et al., 1995), although 
the activity of these enzymes seems to be much higher in peripheral organs, i.e. the 
liver and the kidneys (Stone, 1993; Schwarcz and Pellicciari, 2002). In the periphery 
several aminotransferases responsible for the conversion of kynurenine to kynurenic 
acid have been identified, and a few have been recognized in both the human and the 
rat brain. The first to be identified were KAT I and KAT II, which are preferentially 
expressed in glial cells.  (Okuno et al., 1991a, b; Buchli et al., 1995; Guidetti et al., 
1997). KAT I and KAT II differ from each other with regard to pH optimum and 
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substrate specificity, where KAT II operates best at physiological pH, shows the 
highest specificity to kynurenine and is primarily responsible for kynurenic acid 
formation in the brain (Schmidt et al., 1993; Guidetti et al., 1997). Thus, studies suggest 
KAT II accounts for >70% of the KYNA production in the rat (Guidetti et al., 1997). 
However, both KAT I and KAT II have Km in the millimolar range, suggesting that the 
availability of kynurenine is the rate limiting step of kynurenic acid synthesis. Two 
additional enzymes converting kynurenine to kynurenic acid have been discovered in 
the mammalian brain, KAT III and mitochondrial aspartate aminotransferase, but 
whether these enzymes play a significant role in synthesis of kynurenic acid remains to 
be clarified (Yu et al., 2006; Guidetti et al., 2007). The transamination of kynurenine by 
KATs, forming kynurenic acid, is irreversible and no further enzymatic steps appear to 
occur. Importantly, kynurenic acid, due to its polar structure, is unable to pass the blood 
brain barrier (Fukui et al., 1991). Thus, after release from astrocytes into the 
extracellular space, the only clearing alternative for kynurenic acid is via a probenecid-
sensitive transporter out of the brain (Moroni et al., 1988a). Once kynurenic acid 
reaches the blood, it is rapidly excreted through the renal filtration (Turski and 
Schwarcz, 1988). 
 
Kynurenic acid is an antagonist of glutamate receptors in the human brain; in low 
doses, the compound blocks the glycine site of the NMDA receptor (IC50  ~8-15 µM; 
Ganong and Cotman, 1986; Kessler et al., 1989; Parsons et al., 1997; Birch et al., 1988) 
as well as the α7*nACh receptors (IC50 ~7 µM; Hilmas et al., 2001). At higher 
concentrations also the glutamate recognition site of the NMDA receptor (IC50 = 200-
500 µM; Kessler et al., 1989) and the alpha-amino-3-hydroxy-5-methylisoxazole 
propionate (AMPA)/kainate receptors are blocked (IC50 in the millimolar range; 
Bertolino et al., 1989; Kessler et al., 1989).  Furthermore, kynurenic acid is also an 
endogenous agonist of the G protein-coupled receptor 35 (GPR35; EC50 = 39 µM for 
human). GPR35 is predominantly detected in immune cells and the gastrointestinal 
tract whereas its expression is limited in the brain (Wang et al., 2006). Recently, it was 
also reported that low levels of kynurenic acid facilitate AMPA receptor responses in 
Xenopus oocytes but not in rat hippocampal slices (Prescott et al., 2006). 
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1.4.2   Regulation of synthesis 
The synthesis of kynurenic acid is mainly driven by the intracellular concentration of 
L-kynurenine (Schwarcz and Pellicciari, 2002). Thus, the concentration of kynurenic 
acid in the brain increases following systemic injections of kynurenine in both rats and 
primates (Swartz et al., 1990; Wu et al., 1992; Jauch et al., 1993). Furthermore, levels 
of kynurenic acid also increase by inhibiting the conversion of kynurenine to 3-
hydroxykynurenine (Russi et al., 1992; Speciale et al., 1996; Erhardt et al., 2009), i.e. 
by drugs blocking kynurenine 3-hydroxylase. Hereby, the metabolism of kynurenine is 
driven towards the other branch of the kynurenine pathway, i.e. to the formation of 
kynurenic acid. 
 
Amino acids, e.g. glutamine and phenylalanine, are competitive substrates of KAT I 
and KAT II, and thus, intracellular concentrations of these compound are suggested to 
control the production of kynurenic acid (Chang et al., 1997). Furthermore, the efflux 
of kynurenic acid from the brain is dependent on large amino acid carriers, and 
inhibition of this process, e.g. with probenecid, results in increased kynurenic acid 
levels in the brain (Moroni et al., 1988). Studies have also shown that inhibition of 
COX-1, e.g. by administration of indomethacin or diclofenac, is associated with 
increased levels of kynurenic acid in the brain (Edwards et al., 2000; Schwieler et al., 
2005; 2006). Furthermore, systemic administration of COX-2 inhibitors, e.g. parecoxib 
and meloxicam, decrease brain levels of kynurenic acid (Schwieler et al., 2005; 2006). 
Moreover, the rate limiting enzymes in the kynurenine pathway, i.e. IDO and TDO (see 
1.4), are induced by immunological agents, e.g. pro-inflammatory cytokines like 
interferon-γ, that induce the entire cascade of the kynurenine pathway (Yoshida et al., 
1986; Carlin et al., 1987). Also, the expression of KAT I and KAT II is induced by 
interferon-γ, hence increasing the synthesis and release of kynurenic acid by astrocytes 
(Guillemin et al., 2001). The biological significance of the induction of the kynurenine 
pathway by immunological agents is not fully understood. However, it has been 
suggested that increased tryptophan breakdown serves as a defense mechanism for 
reducing the supply of tryptophan needed by pathogens (Pfefferkorn, 1984; Moffet and 
Namboodiri, 2003). 
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1.5  The glutamate system of the brain 
Glutamate is one of the ordinary 20 amino acids in the body and one of the primary 
neurotransmitters in the mammalian brain. When first investigated it was not 
considered to fulfill the criteria as a neurotransmitter, but today glutamate is classified 
as one of the so called excitatory amino acid (EAA) and known to be involved in most 
aspects of brain function, e.g. cognition, memory and learning (McEntee and Crook, 
1993). Thus, it is well known that glutamate accounts for most of the fast excitatory 
signaling in the vertebrate nervous system (Orrego and Villanueva, 1993). However, 
massive activation of glutamate receptors may lead to neuronal damage and even to cell 
death, so-called excitotoxicity (Meldrum and Garthwaite, 1990; Choi, 1992). 
Therefore, astrocytes that surround the synaptic cleft are of major importance for 
regulating the extracellular concentration of glutamate. Clearance of glutamate is 
ensured by diffusion and by specific transporters located on both neurons and 
astrocytes. In astrocytes, accumulated glutamate is converted to glutamine, released 
again and converted back to glutamate by neurons. This process is referred to as the 
glutamate-glutamine cycle and enables glutamate to be recycled and transported back 
to neurons in an inactive and non-toxic form (Danbolt et al., 2001).  
 
The receptors mediating the effects of glutamate are divided into four subtypes, 
NMDA, AMPA, kainate and metabotropic glutamate receptors (mGluR; Ozawa et al. 
1998). NMDA, AMPA and kainate are ionotropic receptors, i.e. ligand gated ion 
channel receptors, whereas the mGluRs are linked to G proteins and act through a 
second messenger (Seeburg, 1993; Ozawa et al., 1998). The endogenous agonists for 
all these receptors are generally believed to be glutamate and/or aspartate and the only 
known naturally occurring antagonist of the ionotropic EAA receptors is kynurenic acid 
(see 1.4.1). 
 
1.5.1  The NMDA receptor 
The NMDA receptor is widely distributed throughout the brain and known to play a 
critical role in synaptic plasticity, a cellular mechanism for learning and memory. 
Several subunits of the NMDA receptor have been identified; NR1, NR2 and NR3 
(Paoletti and Neyton, 2007). All NMDA receptors appear to function as heteromeric 
complexes and require the co-expression of at least one NR1 and one NR2 subunit 
Klas Linderholm 
 
 24 
(Paoletti and Neyton, 2007). Furthermore, the subunits have distinct binding sites and 
thus the NMDA receptor is a quite complex receptor. At resting membrane potential 
the channel of the NMDA receptor is blocked by Mg2+, which is removed upon 
depolarization of the cell, e.g. by AMPA receptor activation (McBain and Mayer, 
1994). In addition, the NMDA receptor requires the presence of a co-agonist, glycine or 
D-serine, on the NR1 subunit to function (fig. 2; Paoletti and Neyton, 2007; Hirai et al., 
1996). Thus, the NMDA receptor is unique in that it requires membrane depolarization, 
removing the Mg2+, and also simultaneous co-activation by two ligands, 
glutamate/aspartate and glycine/D-serine, to be activated. In addition, the function of 
the receptor can also be modified by extracellular Zn2+ and polyamines (Danysz and 
Parsons, 1998). It has previously been claimed that the glycine/D-serine site might be 
constantly occupied under normal conditions (Obrenovitch et al., 1997), however, 
several studies have demonstrated that this site is not saturated in vivo (Danysz and 
Parsons, 1998). Thus, the availability of glycine and/or D-serine appears of critical 
importance for optimal NMDA receptor functioning. The activated NMDA receptor is 
permeable for both K+ and Na+, but has 
particular high permeability for Ca2+, 
which acts as a second messenger in the 
cell. The increased Ca2+, due to high 
glutamatergic activity, results in a 
permanent increase in synaptic efficacy. 
This process is known as long term 
potentiation (LTP; Lynch, 2004) and is of 
critical importance for learning and 
memory. However, there is a gentle 
balance and excessive Ca2+ leads to excitotoxicity (see 1.5). 
 
1.6  The dopamine system 
Dopamine was recognized as a neurotransmitter of its own rights in the late 1950s 
(Carlsson et al., 1957; 1958; Carlsson, 1959). Prior to this point dopamine was 
considered only as an intermediate in the synthesis of noradrenaline and adrenaline. 
Today we know that dopamine, noradrenaline and adrenaline are metabolites of the 
amino acid tyrosine. Due to their mutual chemical structure, i.e. a nucleus of catechol 
and a side chain of ethylamine or one of its derivates, these compounds are described as 
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catecholamines. The dopamine system has been extensively investigated and the 
transmitter is considered a key modulator in numerous functions of the brain, e.g. 
behavior, cognition, voluntary movement and reward. The effects of dopamine are 
mediated through dopamine receptors, subgrouped into dopamine D1-like receptors and 
dopamine D2-like receptors (Jaber et al., 1996). The receptors in both of the subgroups 
are localized pre- as well as postsynaptically, where presynaptic dopamine D2 receptors 
act as autoreceptors, providing important inhibitory feedback to the dopamine neuron 
(Stoof and Kebabian, 1984; White and Wang, 1984). 
 
1.6.1  Dopamine pathways 
Studies of the dopamine system have identified three major dopamine pathways. The 
cell bodies of these projections are located in the substantia nigra, ventral tegmental 
area (VTA) and in the arcuate and periventricular hypothalamic nuclei (Dahlström and 
Fuxe, 1964). The dopamine neurons of substantia nigra project to the dorsal part of the 
striatum, i.e. the caudate and the putamen, via the medial forebrain and the internal 
capsule. This projection is referred to as the nigrostriatal dopamine pathway and of 
critical importance for motor function (Carlsson, 1959; Ehringer and Hornkiewicz, 
1960; Andén et al., 1964). Degeneration of these neurons causes Parkinson´s disease 
and inhibition of this system, e.g. by antipsychotic drugs, is associated with EPS (see 
1.1.1). From the VTA, dopamine neurons project, via the medial forebrain bundle, to 
cortical and subcortical (limbic) areas, thus forming the mesolimbocortical pathway. 
This pathway is further subdivided into the mesolimbic dopamine system, projecting to 
amygdaloid complex, nucleus accumbens, olfactory tubercle and septal area, and the 
mesocortical dopamine system, projecting to areas in the prefrontal cortex, such as 
prelimbic, infralimbic and cingule cortices (Dahlström and Fuxe, 1964; Andén et al., 
1966; Ungerstedt, 1971; Moore and Bloom, 1978; Björklund and Lindvall, 1984). 
These pathways are crucial for processes such as motivation, reward and cognition 
(Fibiger and Phillips, 1988; LeMoal and Simon, 1991; Schultz et al., 1993; Schultz, 
1998), domains frequently disturbed in patients with schizophrenia (see 1.1). The 
tuberohypophysial dopamine system originates in the hypothalamus and projects to the 
median eminence and the intermediate and posterior lobes of the pituitary. This 
pathway is involved in the control of endocrine functions and thus responsible for 
Klas Linderholm 
 
 26 
endocrine-related side effects of antipsychotic drugs, e.g. sexual dysfunction, infertility, 
gynecomastia and galactorrhea. 
1.6.2  Electrophysiology of midbrain dopamine neurons 
Firing of dopamine neurons has been thoroughly investigated in electrophysiological 
studies ranging from in vitro recordings of isolated neurons to activity recordings of 
freely moving primates. These studies have revealed that dopamine neurons alternate 
between spontaneous firing, at frequencies of 1-10 Hz, and states of silence (Grace and 
Bunney, 1984a). Furthermore, there are two basic modes of firing of these neurons: an 
irregular and relatively slow single spike firing or a relatively rapid burst firing (Wang, 
1981; Grace and Bunney, 1984a; b; Clark and Chiodo, 1988). When firing in burst 
mode, spikes within the burst exhibit progressively decreasing spike amplitude as well 
as increased spike duration. The different firing patterns of midbrain dopamine neurons 
appear fundamental for transmitter release in terminal areas, as a switch from single 
spike firing to burst firing is associated with a massive release of dopamine, and 
accordingly, when burst firing is dampened, the release decreases (Gonon, 1988; 
Nissbrandt et al., 1994). In freely moving rats over 90% of VTA dopamine neurons 
exhibit burst firing (Freeman and Bunney, 1987), whereas up to 50% of spontaneously 
active midbrain dopamine neurons fire in bursts in anaesthetized rats (Grace and 
Bunney, 1984a; Clark and Chiodo, 1988). This discrepancy is suggested to be due to 
the degree of sensory stimulation or to the interaction between movement and 
stimulation. Supporting this notion, many experiments show that burst firing of 
midbrain dopamine neurons is induced by food and fluid rewards as well as reward-
related tasks in monkeys (Schultz et al., 1993; Schultz, 1998). 
 
1.6.3  Afferent regulation of dopamine neurons in ventral tegmental area 
There are significant differences between spontaneous firing of VTA dopamine 
neurons in vivo and in vitro. Most prominent is the fact that burst firing is not seen in 
slice preparation, suggesting that afferent inputs drive the firing of dopamine neurons 
(Sanghera et al., 1984; Grace and Onn, 1989; Seutin et al., 1990; Johnson et al., 1992). 
Most important in this regard are inhibitory GABAergic and stimulatory glutamatergic 
inputs. Extrinsic GABAergic neurons project to the VTA from areas such as nucleus 
accumbens and frontal cortex (Walaas and Fonnum, 1980; Yim and Mogenson, 1980; 
Kalivas et al., 1993). Furthermore, in the VTA approximately 15-20% of the total 
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neuronal population consists of intrinsic GABAergic interneurons (Beart and 
McDonald, 1980; Kalivas et al., 1993; Van Bockstaele and Pickle, 1995). Interestingly, 
these neurons not only synapse on dopamine neurons but also project to the nucleus 
accumbens and the prefrontal cortex (Thierry et al., 1980; Kalivas, 1993; Van 
Bockstaele and Pickel, 1995; Steffensen et al., 1998; Carr and Sesack, 2000a). 
 
The effects of GABA, the main inhibitory neurotransmitter in the brain, on dopamine 
neurons is exerted via GABAA and GABAB receptors, both expressed on VTA 
dopamine neurons (Churchill et al., 1992; Wirtshafter and Sheppard, 2001). Thus, in 
vivo electrophysiological studies have shown that stimulation of GABAB receptors by 
baclofen is associated with a reduction of midbrain dopamine cell firing (Engberg et al., 
1993; Erhardt et al., 1998; 2002). Furthermore, systemic administration of a selective 
GABAB receptor antagonist has been shown to increase dopamine cell firing, 
suggesting a tonic inhibitory control of midbrain dopamine neurons by these receptors 
(Erhardt et al., 1999; 2002). However, when administrating GABAA receptor agonists, 
in vivo electrophysiological studies 
have shown a paradoxical increase in 
firing activity of VTA dopamine 
neurons (Waszczak and Walters, 1980). 
This excitatory effect of GABAA 
agonists is suggested to be related to 
disinhibition of dopamine neurons 
(Grace and Bunney, 1979; Waszczak et 
al., 1980). Furthermore, it has also been 
suggested that the excitatory actions of 
GABAA agonists on VTA dopamine 
neurons are mediated via release of the 
excitatory transmitter glutamate 
(Erhardt and Engberg, 2002). 
 
The major glutamatergic input to the VTA originates from the prefrontal cortex and the 
pedunculopontine nucleus, and is important for the induction of burst firing activity 
(Carr and Sesack, 2000b; Charara et al., 1996). Thus, stimulation or inactivation of the 
prefrontal cortex increases or decreases burst firing activity of VTA dopamine neurons, 
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respectively (Murase et al., 1993). The glutamatergic afferents are connected with both 
GABAergic interneurons and dopaminergic cells, projecting back to the prefrontal 
cortex (fig. 3; Bonci and Malenka, 1999; Carr and Sesack, 2000b). Thus, the activity of 
VTA dopamine neurons by glutamatergic afferents is regulated both directly, by 
afferents synapsing on dopamine neurons that project to the prefrontal cortex, and 
indirectly, by glutamatergic afferents synapsing on GABAergic interneurons. The 
GABAergic interneurons in turn synapse on dopamine neurons projecting to the 
nucleus accumbens (fig. 3; Carr and Sesack, 2000b). The effects of glutamate in this 
regard can be mediated by both metabotropic and ionotropic receptors (see 1.5), which 
are shown to be present in the VTA (Seutin et al., 1990; Albin et al., 1992; Paquet et 
al., 1997). However, the ionotropic NMDA receptors have gained the highest level off 
attention over the years, and studies have shown that systemic administration of non-
competitive NMDA receptor antagonists, e.g. PCP and MK-801, inhibit GABAergic 
interneurons (Zhang et al., 1993). This effect appears to cause a disinhibition of VTA 
dopamine neurons as systemic administration of non-competitive NMDA receptor 
antagonists is associated with increased burst firing of VTA dopamine neurons as well 
as increased dopamine release in the nucleus accumbens (French et al., 1993; Murase et 
al., 1993a; French, 1994; Schmidt et al., 1996; Yan et al., 1997; Kretschmer, 1999). 
Interestingly, NMDA receptor antagonists are known to induce psychotomimetic 
effects in humans and thus provide profound evidence for the glutamate deficiency 
theory of schizophrenia (see 1.2.2).  
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2 SPECIFIC AIMS OF THE STUDY 
  
1. To study the mechanism involved in the excitatory action of elevated 
levels of endogenous kynurenic acid on VTA dopamine firing as well as 
in its disruptive effects on PPI. 
 
2. To examine the actions of clozapine on glutamatergic neurotransmission 
by investigating its effect on VTA dopamine neurons following 
manipulation of endogenous levels of brain kynurenic acid. 
 
3. To analyze kynurenic acid and its precursors, tryptophan and 
kynurenine, in the CSF of patients with schizophrenia and healthy 
volunteers. 
 
4. To analyze levels of kynurenic acid and its relation to pro-inflammatory 
cytokines and chemokines in the CSF of healthy male volunteers and 
male suicide attempters with well-defined clinical psychiatric profiles.  
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3 MATERIALS AND METHODS 
 
3.1 Animals 
In all animal experiments male Sprague-Dawley rats (B&K Universal AB, Sollentuna, 
Sweden; weighing between 200 and 330 g) were used. The animals were housed in 
groups of five with free access to food and water. Environmental conditions were 
checked daily and maintained under constant temperature (25oC) and 40-60% humidity 
with a regulated 12-h light/dark cycle. For electrophysiological experiments (paper I 
and III) rats were housed in a daily cycle of lights on at 06.00 AM and lights off at 
06.00 PM. For behavioral experiments (paper II) the rats were housed in a room with a 
regulated, reversed 12-h light/dark cycle, with lights off at 07.00 AM and lights on at 
07.00 PM. Rats were kept in this room for two weeks prior to experiments to adjust 
diurnal rhythm. In the behavioral experiments, the animals were handled at least 2 days 
preceding the experiments to reduce any subsequent handling stress. Experiments were 
approved by and performed in accordance with the guidelines of the Ethical Committee 
of Northern Stockholm, Sweden, and all efforts were made to minimize the number of 
animals used and their suffering. 
 
3.2 Drugs 
The following drugs were used: 4-chloro-kynurenine (4-Cl-KYN), precursor to the 
selective NMDA glycine site antagonist 7-chloro-kynurenic acid (7-Cl-KYNA), kindly 
supplied by Vistagen Therapeutics, South San Francisco, CA, USA; L-kynurenine, 
precursor to kynurenic acid, Sigma, St. Louis, MO, USA; CGS 19755, competitive 
NMDA receptor antagonist, Tocris, Avonmouth, UK; SDZ 220-581, competitive 
NMDA receptor antagonist, Tocris, Avonmouth, UK; L-701,324, selective NMDA 
glycine site antagonist, Sigma, St. Louis, MO, USA; methyllycaconitine (MLA), 
α7*nACh receptor antagonist, Sigma, St. Louis, MO, USA; parecoxib, selective COX-
2 inhibitor, Pharmacia, Buckinghamshire, Great Britain; indomethacin, COX-1 > COX-
2 inhibitor, A/S Dumex Ltd. Copenhagen, Denmark; clozapine, atypical antipsychotic 
drug, Sigma, St. Louis, MO, USA; chloral hydrate, general anesthetic drug, Merck, 
Darmstadt, Germany; isoflurane, general anesthetic drug, Abbott Scandinavia, Solna, 
Sweden. 
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3.3  In vivo electrophysiology 
 
3.3.1 Anesthesia and surgery 
Rats were weighed and thereafter anesthetized with 8% chloral hydrate (400 mg/kg, 
i.p.). For best induction of general anesthesia, rats were left in a quiet environment for 
approximately 10-15 min. If the degree of anesthesia was not satisfactory by the end of 
this period an additional 8% chloral hydrate (200 mg/kg, i.p.) was administered. The rat 
was then placed on a heating pad to maintain body temperature at 37°C and 
subsequently mounted to the ear-bars of a conventional stereotaxic frame (David Kopf 
Instruments, Tujunga, CA, USA). The skull was set in a horizontal position and the 
nose was secured using a clamp at the front of the frame. For i.v. administration a 
cannula was inserted into a lateral tail vein and secured with strips of adhesive tape. A 
syringe containing 0.9% NaCl was connected to the cannula and approximately 0.5 mL 
was injected to assure a proper position of the cannula. An incision was made with a 
scalpel from the nose bridge along the center of the head to its base and the skull 
surface was exposed. For recordings from the VTA a burr hole of approximately 3 mm 
in diameter was drilled immediately anterior to lambda and lateral to the midline on the 
right side of the skull. The dura was carefully removed using a needle and a pair of 
tweezers. Additional chloral hydrate was administered through the tail vein when 
required to maintain a stable level of anesthesia. The level of anesthesia during the 
experiments was determined from the response following a hind paw pinching and by 
observing the breathing pattern. When required, additional 8% chloral hydrate was 
administered through the tail vein to maintain a stable level of surgical anesthesia. 
 
3.3.2 Preparation of recording electrode 
Single barrel recording electrodes were prepared from glass capillaries (Harvard 
Apparatus, inner diameter 1.16 mm) pulled in a vertical electrode puller (Narishige, 
Japan) set at 14.5 amperes. The electrode was filled with 0.5 M sodium acetate (Riedel-
de Haen, Germany) saturated with Pontamine Sky Blue (BDH Laboratory Supplies, 
UK) and the tip was broken under a microscope to a diameter of approximately 1-2 µm. 
The in vitro impedance of the electrode was measured in a microelectrode tester. The 
impedance was typically 5-8 MΩ measured at 135 Hz in 0.9% saline. 
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3.3.3 Extracellular single cell recording 
The recording electrode was secured onto a hydraulic microdrive (David Kopf 
Instruments, Tujunga, CA, USA) mounted to the stereotaxic instrument. The 
coordinates for lambda were visually estimated, placing the tip of the electrode just 
above lambda without touching the skull and the coordinates for VTA were set in 
relation to that. According to the stereotaxic coordinates from the atlas of Paxinos and 
Watson (1998) VTA was set to approximately 3.0 mm anterior to lambda and 0.7 mm 
lateral to the midline. The recording electrode was vertically lowered until its tip 
touched the brain surface, which caused a signal on the oscilloscope. The microdrive 
counter was set to zero and the electrode was lowered into the brain to a depth of 
approximately 7.0 mm. From this point the electrode was lowered slowly, using the 
hydraulic microdrive, into VTA where dopamine neurons were found 7.5-8.5 mm from 
the brain surface. Single unit potentials from electrophysiologically identified 
dopamine neurons were passed through a high input impedance amplifier and filters. 
The impulses were discriminated from background noise and fed into a computer, 
simultaneously displayed on a digital storage oscilloscope, monitored on an audio 
monitor and on a strip chart recorder (Gould). After each experiment the rat was killed 
with an overdose of chloral hydrate and the brain was rapidly removed and stored at -
70°C until subsequent analysis. The recording sites of the experiments were not 
verified histologically since the brains were used for identification of kynurenic acid or 
7-Cl-KYNA. Instead, dopaminergic neurons were mainly identified based upon their 
typical neurophysiological characteristics (see below) and, when appropiate, the 
inhibitory action of a single dose of the dopamine agonist apomorphine at the end of 
the experiments. 
 
3.3.4 Electrophysiological characteristics of dopaminergic neurons 
Dopamine neurons were identified using the electrophysiological characteristics 
previously described for midbrain dopamine neurons (Wang, 1981; Grace and Bunney, 
1984a, b) including: 
1. A biphasic (positive – negative) or triphasic (positive – negative – positive) 
waveform, often with a prominent inflection in the initial phase. 
2. An action potential of long duration (2.5-4.0 ms), giving a characteristic low 
pitched sound on the audio monitor. 
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3. A slow, irregular firing pattern with a frequency between 1 and 9 Hz, 
sometimes alternating with bursts of high frequency spike activity and 
decreasing amplitude of spikes within each burst. 
 
3.3.5 Drug administration and experimental protocol 
Drugs were administered via the lateral tail vein or i.p. into the abdomen before or 
during the electrophysiological experiments. The basal activity, i.e. firing rate and 
percentage of spikes fired in bursts, was recorded for approximately 3 min before drug 
administration. The effect of a drug on firing was assessed by comparing the basal 
activity with the firing rate and percentage of spikes fired in bursts following each 
incremental dose administered. The firing activity was recorded from only one VTA 
dopamine neuron in each rat in all experiments in paper III and in the analysis of the 
response to MLA and SDZ 220-581 in paper I. In rats pretreated with kynurenine or 4-
Cl-KYN in paper I, an average of 7 neurons were analyzed in each rat to estimate 
electrophysiological characteristics following 1-3.5 h drug pretreatment. In these 
experiments, the electrode was moved 0.1 mm between each track in a pattern that 
ensured that cells were recorded from only once. The number of spontaneously firing 
dopamine cells in VTA was calculated from the number of cells found per track. In 
paper III, rats were pretreated with a COX-1 inhibitor (indomethacin, 50 mg/kg, i.p., 1-
3.5 h, n = 9) or COX-2 inhibitor (parecoxib, 25 mg/kg, i.v., 1-1.5 h, n = 12) in order to 
increase or decrease endogenous brain levels of kynurenic acid, respectively. Previous 
studies have shown that such treatment with indomethacin is associated with 153% 
elevation of brain kynurenic acid levels as well as an increase in firing rate and 
percentage of spikes fired in bursts in midbrain dopamine neurons (Schwieler et al., 
2005, 2006). Additionally, pretreatment with parecoxib has shown 52% decrease in 
brain levels of kynurenic acid as well as a decrease in dopamine firing activity 
(Schwieler et al., 2006). Therefore, efforts were made to avoid recording of dopamine 
neurons with very high or very low frequency and burst firing activity. Furthermore, in 
line with a previous study (Erhardt and Engberg, 2002) 25% of all VTA dopamine 
neurons in rats with elevated levels of kynurenic acid occasionally showed 
depolarization-block characteristics. This effect was also seen occasionally in rats with 
elevated brain levels of 7-Cl-KYNA and such neurons were excluded from further 
analysis. 
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3.3.6 Influence of anesthesia 
The influence of anesthetics as a confounding factor on neuronal activity and afferent 
responsiveness remains unclear and care must be taken in the interpretation of results 
obtained in anesthetized animals to infer normal function. The firing patterns of 
dopamine neurons in anesthetized, paralyzed and freely moving rats are similar in some 
respects but different in others; for example, higher burst frequencies are found in 
freely moving rats compared to anesthetized and paralyzed rats (Freeman and Bunney, 
1987; Overton and Clark, 1997; Hyland et al., 2002). Previous reports have shown that 
the primary metabolite of chloral hydrate, trichloroethanol (presumably responsible for 
the depressant effects of chloral hydrate in the nervous system, Breimer, 1977), impairs 
NMDA receptor activation (Peoples and Weight, 1998; Scheibler et al., 1999). 
Furthermore, it has been shown that chloral hydrate decreases extracellular levels of 
synaptically released glutamate in the striatum (Kreuter et al., 2004). These influences 
on the glutamatergic system may interact with our experiments and also with the effects 
of elevated levels of kynurenic acid or 7-Cl-KYNA on dopamine cell firing. However, 
since all rats were anesthetized with chloral hydrate using the same routines the 
experiments’ differences in firing activity found between control rats and drug treated 
rats should not be attributable to the anesthesia. 
 
3.3.7 Data analysis 
The distribution of spikes in paper III was analyzed on-line with a Macintosh computer. 
The software used for the analysis of firing was written in-house using high levels 
object oriented programming language called “G” (Lab VIEW; National Instruments, 
Austin, TX, USA). In paper I, the distribution of spikes was analyzed utilizing a Spike 
II software program (Cambridge Electronic Design, Cambridge, England) on a 
Hewlett-Packard Compaq computer. Both software programs were designed to sample 
and analyze the intervals of an arbitrary number of TTL pulses (corresponding to spikes 
passing through the discriminating filter) using a time resolution of one ms. An 
interspike interval was designated as the time (in ms) elapsed between the rising edges 
of two sequential TTL (transistor-transistor logic) pulses. In order to avoid artifacts in 
the sampling procedure, the spike analyzers were set to ignore time intervals below 20 
ms. The onset of a burst was determined as an interspike interval shorter than 80 ms 
and the termination of a burst by the next interval longer than 160 ms (Grace and 
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Bunney, 1984a, b). The intervals were analyzed with regard to the number of bursts 
that occurred during a sampling of 100-500 spikes along with calculation of the 
percentage of spikes fired in bursts. Cells were considered to be bursting if at least one 
interspike time interval of 100 recorded spikes was below 80 ms. 
 
3.4 Microdialysis 
Male rats, weighing between 200 and 250 g, were anesthetized in a Plexiglas chamber 
filled continuously with 4.8% isoflurane (Forene®, Abbott Scandinavia, Solna, 
Sweden) in air using a vaporizer (Univentor 400, Malta). For the best induction of 
general anesthesia, rats were left in a quiet environment for approximately 5 min. 
Thereafter, the rat was mounted in a stereotaxic frame (Stoelting, Wood Dale, IL, USA) 
so that the skull was set in a horizontal position. Anesthesia was maintained using a 
nose cone delivering 2.4% isoflurane throughout the surgery. A hole was drilled in the 
skull and following careful removal of the dura, a guide cannula (AgnTho’s, Lidingö, 
Sweden) was directed to the region of nucleus accumbens and fixated with Dentalon® 
(AgnTho’s, Lidingö, Sweden). Day one after surgery the guide cannula was exchanged 
with a microdialysis probe and experiments was carried out in unanesthetized freely 
moving rats. The probe was perfused with perfusion fluid (NaC1, 147.0; KC1, 2.7; 
CaC12, 1.2; and MgC12, 0.85 mM; CMA Microdialysis AB, Solna, Sweden) at a flow 
rate of 1 mL/min (infusion pump, Univentor 864, Malta). For analysis of kynurenic 
acid and 7-Cl-KYNA acid, forty- and thirty-minute fractions were collected (Univentor 
820 Microsampler, Malta), respectively, and injected into an HPLC column. When the 
experiment was terminated, the rat was decapitated. Coronal sections (50 mm thick) 
were made using a cryostat (SLEE Medical GmbH, Mainz, Germany), and correct 
dialysis-probe placement was verified according to the atlas of Paxinos and Watson 
(1998). Stereotaxic coordinates of the implantation were 1.6 mm anterior and 1.4 mm 
lateral with reference to the bregma and lowered 8.2 mm from the brain surface. No 
distinction could be made between the core and the shell of the nucleus accumbens.  
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3.5 Prepulse inhibition 
 
3.5.1 Apparatus 
For measuring the startle response two startle chambers were used (SR-LAB, San 
Diego Instruments, San Diego, CA, USA). Each chamber consisted of a Plexiglas 
cylinder (9 cm diameter) mounted on a frame, housed within a ventilated chamber (39 
x 38 x 58 cm). Sudden movements within the cylinder were detected by a piezoelectric 
accelerometer attached below the cylinder. A loudspeaker (Radio Shack Supertweeter) 
mounted 24 cm above the cylinder provided the broadband background noise and 
acoustic stimuli. Presentations of the acoustic stimuli were controlled by the SR-LAB 
software and interface system, which also rectified, digitized (0-4095) and recorded 
responses from the accelerometer. Sound levels [dB(A) scale] and accelerometer 
sensitivities within each chamber were calibrated regularly, as described earlier 
(Mansbach et al., 1988), and found to remain constant over the test period. 
 
3.5.2 Experimental protocol 
To elevate levels of endogenous brain kynurenic acid, rats (n = 14) were pretreated 
with kynurenine (200 mg/kg) i.p. 60 min before testing. Control rats (n = 13) received 
vehicle i.p. 60 min before testing for comparison with animals treated with kynurenine. 
In order to block the glutamate recognition site of the NMDA receptor, rats were 
pretreated with SDZ 220-581 (2.5 mg/kg, n = 12) s.c. 30 min before testing or CGS 
19755 (10 mg/kg, n = 12) s.c. 45 min before testing. For these experiments, rats 
receiving saline (n = 12) s.c. 30 min before testing, were used as controls. In a third 
experiment, rats were treated with drugs blocking the glycine-site of the NMDA 
receptor or the α7*nACh receptor. In order to block the glycine-site of the NMDA 
receptor, in situ produced 7-Cl-KYNA or pretreatment with L-701,324 (1 mg/kg, n = 
13 or 4 mg/kg, n = 17) i.p. 15 min before testing were used. To produce 7-Cl-KYNA in 
situ, rats were pretreated with 4-Cl-KYN (25 mg/kg, n = 15; 50 mg/kg, n = 14; or 100 
mg/kg, n = 10) i.p. 60 min before testing. For selective blocking of the α7*nACh 
receptor, rats were treated with MLA (6 mg/kg, n = 15) i.p. 10 min before testing. 
Controls in this study (n = 18) received saline i.p. 15 min before testing. All drug 
combinations were balanced across the two startle chambers. The experimental session 
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consisted of a 5 min acclimatization period to a 65-dB background noise (continuous 
throughout the session), followed by a 20 min acoustic PPI test session. Seven days 
before any drug testing, animals were pre-exposed to the chambers and the testing 
session. The purpose of the pre-exposure was to acclimatize the animals to the testing 
chambers and startle/prepulse stimuli and to baseline-match the groups for subsequent 
testing (groups were matched for equivalent mean startle magnitude and percent PPI, as 
defined below). In the test session, a background noise (65 dB) was presented alone for 
5 min and then continued throughout the remainder of the session. The test session used 
in all of the experiments contained five different trial types and had a duration of 20 
min: a “pulse-alone” trial, in which a 40-ms 120-dB broadband burst was presented; 
three “prepulse-pulse” trials, in which 20-ms stimuli that were either 3, 6, or 12 dB 
above the background noise were presented 100 ms before the onset of the 120-dB 
pulse; and a “no stimulus” trial, which included only the background noise. All trial 
types were presented several times in a pseudorandom order for 60 trials (12 pulse-
alone trials, 10 each of the remaining prepulse trial types, and eight no-stimulus trials). 
Five pulse-alone trials, which were not included in the calculation of PPI values, were 
presented at the beginning of the test session to achieve a relatively stable level of 
startle reactivity for the remainder of the session (based on the observation that the 
most rapid habituation of the startle reflex occurs within the first few presentations of 
the startling stimulus (Geyer et al., 1990)). In addition, five pulse-alone trials occurred 
at the end of the session to assess startle habituation but were not included in the 
calculation of PPI. An average of 15 sec (range 9-21 sec) separated consecutive trials. 
The whole session lasted approximately 24 min. The brief baseline session used to 
familiarize rats with the testing procedure and match groups for pharmacological 
studies consisted of 24 trials (18 120-dB pulse-alone and six prepulse-pulse trials with a 
12-dB prepulse intensity).   
 
3.6 Sampling of human cerebrospinal fluid 
 
3.6.1 Ethical aspects 
The work described in the studies was carried out in accordance with “The code of 
ethics of the World Medical Association” (Declaration of Helsinki) for experiments 
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including humans: http://www.wma.net/e/policy/b3.htm. All enrolled patients 
consented orally and in writing to participate in the study. The studies were approved 
by the Regional Ethical Committee in Linköping, Lund and Malmö. 
 
3.6.2 Subjects 
In paper IV, 24 patients, aged 36.8 years ± 7.9 (mean ± SD), range 23-49 years, with a 
DSM-IV (fourth edition, American Psychiatric Association 1994) verified 
schizophrenia were enrolled in the study. Patients consisted of 16 males, aged 36.8 
years ± 7.9 (mean ± SD), range 23-49 years, and 8 females, aged 35.9 years ± 6.6 
(mean ± SD), range 26-46 years. All patients were prescribed and taking olanzapine 
(2.5-25 mg/day) as the only antipsychotic drug. 44 healthy volunteers (29 male, 15 
female), aged 24.9 years ± 6.2 (mean ±SD), range 18-51 years, mainly recruited among 
medical students, hospital staff members and their relatives, via the University Hospital 
in Linköping, Sweden, were used as controls.  
 
Patients in paper V were enrolled in the study at Lund University Hospital after a 
suicide attempt between the years of 1987 and 2001. Patients with diabetes, current 
antibiotic treatment as well as all patients who received antidepressant or neuroleptic 
drugs during a wash-out period of 16 ± 7 (mean ± SD) days after the suicide attempt 
were excluded from analyses in the current study. Fifty-four male suicide attempters, 
with a mean age of 36 ± 11 (mean ± SD) years, range 19-61 years, and without traces 
of antidepressant or neuroleptic medication in their blood samples were found to be 
suitable for the present study. Occasional doses of benzodiazepines were allowed 
during the wash-out period, but no tranquilizers were given during the night before the 
lumbar puncture. After the wash-out period, a lumbar puncture and a psychiatric 
evaluation were carried out, as described below. Patients were diagnosed according to 
the Diagnostic and Statistical Manual of Mental Disorders, third edition, revised (DSM 
III-R; American Psychiatric Association 1987). In order to identify subjects with 
potential infections at the time of the lumbar punctures, blood samples were taken from 
all patients and healthy volunteers included in this study for analysis of inflammatory 
and hematological markers (white blood cell count, erythrocyte sedimentation rate or 
C-reactive protein, hemoglobin, glucose or glycosylated hemoglobin, thyroid 
stimulating hormone, liver enzymes and creatinine). Furthermore, all subjects were 
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checked for fever. No signs of ongoing infection was found in any of the patients or 
healthy volunteers. The healthy volunteers in paper V were recruited via the 
Neuropsychiatric and Psychiatric Clinics at the University Hospitals in Linköping and 
Stockholm, Sweden. They consisted of 66 males, aged 26 ± 6 (mean ± SD) years, range 
20-51 years.  
 
In both studies, all healthy volunteers were thoroughly checked for psychiatric co-
morbidity by an evaluating psychiatrist and using the Structured Clinical Interview for 
DSM-IV Axis I Disorders (SCID-I; First et al., 1997a). The healthy volunteers also 
completed the SCID-II questionnaire for personality disorders (First et al., 1997b). All 
controls were physically healthy and considered to be eligible for the studies with 
respect to the clinical interview and SCID results. All were considered healthy by the 
psychiatrist performing the examinations, showed no signs of psychiatric or somatic 
illness, or had any laboratory test outside standardized reference values. None of them 
had a family history of major psychosis, suicide in first- or second-degree relatives or 
difficulties in social adjustment at the time of sampling. 
  
3.6.3 Lumbar Puncture 
Lumbar punctures were performed in the morning between 8 and 11 AM, after a night 
of fasting and bed rest, and CSF was drawn from the L4–L5 interspace using a 
standardized protocol with the subject in the right decubitus position. In paper IV, a 
volume of 12 mL CSF was collected in two fractions. Samples were inverted to avoid 
gradient effects, divided into aliquots and frozen at -70°C until assayed. CSF from the 
second fraction (7-12 mL) was used for analysis through out the study.  In paper V, two 
samples of 12 mL (portion 1) and 6 mL (portion 2) were taken and thereafter stored in 
aliquots and frozen in -70°C until analysis. Aliquots from portion 1 were used in this 
study.  
 
3.7 Analysis of kynurenic acid and 7-chloro-kynurenic acid 
 
3.7.1 Sample preparation 
Immediately after each electrophysiological or behavioral experiment the rats were 
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killed by decapitation. The brains were rapidly taken out and stored at -70°C. The 
brains were sonicated with an equal weight of sonication solution (perchloric acid 0.4 
M, Na2S2O5 0.1%, and ethylenediaminetetra-acetate (EDTA) 0.05%). Thereafter 
samples were centrifuged at 20,000 g for 5 min and approximately 40 µL perchloric 
acid (70%) was added to the supernatant. Subsequently the samples were centrifuged 
twice at 20,000 g for 5 min and stored at -70°C. Before analysis, all samples were 
thawed and centrifuged at 20,000 g for 5 min. 
 
3.7.2 High performance liquid chromatography 
Kynurenic acid and 7-Cl-KYNA were analysed with an isocratic reversed-phase high-
performance liquid chromatography system (HPLC), including a dual piston, high 
liquid delivery pump (Bischoff, Leonberg, Germany), a ReproSil-Pur C18 column (4 x 
150 mm. Dr Maisch Gmbh, Ammerbuch, Germany) and a fluorescence detector (Jasco 
Ltd, Hachioji City, Japan) with an excitation wavelength of 344 nm and an emission 
wavelength of 398 nm (18 nm bandwidth). A mobile phase of 50 mM sodium acetate 
pH 6.20 (adjusted with acetic acid) and 7.0 or 10.0% acetonitrile for kynurenic acid or 
7-Cl-KYNA, respectively, was pumped through the reversed-phase column at a flow-
rate of 0.5 mL/min. Samples of 30 or 50 µL were manually injected (ECOM, Prague, 
Czech Republic). Zinc acetate (0.5 M, not pH adjusted) was delivered post-column by a 
peristaltic pump (P-500, Pharmacia, Uppsala, Sweden) at a flow rate of 0.10 mL/min. 
The signals from the fluorescence detector were transferred to a computer for analysis 
with Datalys Azur (Grenoble, France). The retention time of kynurenic acid or 7-Cl-
KYNA was about 7-8 or 16 min, respectively. Initially, the sensitivity of the system 
was verified by analysis of a standard mixture of kynurenic acid with concentrations 
from 0.5 to 30 nM or 7-Cl-KYNA with concentrations from 1 to 100 nM, resulting in a 
linear standard plot. The standard concentrations were used to relate the height of the 
peaks in the chromatogram to the correct concentration of kynurenic acid or 7-Cl-
KYNA in the samples. Kynurenic acid is a stable compound and is not degraded even 
by repeated thawing (Heyes and Quearry, 1990).  
 
3.7.3 Chemicals 
The chemicals used for sample preparation were perchloric acid (Kebo Lab, 
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Stockholm, Sweden), Na2S2O5 (Sigma, St. Louis, MO, USA) and ethylenediaminetetra-
acetate (EDTA; Sigma, St. Louis, MO, USA). For HPLC, zinc acetate and acetic acid 
(Sigma, St. Louis, MO, USA); sodium acetate (Riedel-de Haen, Germany); acetonitrile 
(Labasco, Partille, Sweden); 7-Cl-KYNA (Tocris, Avonmouth, UK) and kynurenic acid  
(Sigma, St. Louis, MO, USA) were used. 
 
3.8 Analysis of tryptophan and kynurenine 
 
3.8.1 High performance liquid chromatography 
Tryptophan and kynurenine were analyzed with an HPLC system. Separation of 
kynurenine and tryptophan was achieved by reversed-phase liquid chromatography 
using a 20 mM NaH2PO4 buffer (not pH adjusted) with 5.0% acetonitrile. The mobile 
phase was delivered by an HPLC pump (Bischoff Chromatography, Leonberg, 
Germany) through a ReproSil-Pur C18 column (4 x 150 mm, Dr Maisch GmbH, 
Ammerbuch, Germany) at a rate of 0.5 mL/min. Samples of 50 µL were thawed at 
+4°C and manually injected immediately (Rheodyne, Cotati, CA, USA). Following 
separation, the analysate was first passed through a guard cell with an oxidizing 
potential of 50 mV. Samples were then quantified by sequential oxidation and reduction 
in a high-sensitivity analytical cell (ESA 5011; ESA Inc., Chelmsford, MA, USA) 
controlled by a potentiostat (Coulochem III; ESA Inc.) with an applied potential of 600 
mV for detection of kynurenine and tryptophan. The signals from the detector were 
transferred to a computer for analysis (Datalys Azur, Grenoble, France). The retention 
time of kynurenine was approximately 8-9 min and 15-16 min for tryptophan. The 
sensitivity of the system was verified by analysis of standard mixtures of kynurenine, 
with concentrations from 5 to 100 nM, and tryptophan, with concentrations from 0.5 to 
5 µM, resulting in a linear standard plot. The heights of the peaks in the chromatogram 
were used to relate the concentrations of the samples to the standard plot. 
 
3.8.2 Chemicals 
For HPLC, NaH2PO4 (Sigma, St. Louis, MO, USA); acetonitrile (Labasco, Partille, 
Sweden); L-kynurenine (Sigma, St. Louis, MO, USA) and tryptophan (Sigma, St. 
Louis, MO, USA) were used. 
Klas Linderholm 
 
 42 
3.9  Analysis of cytokines and chemokines  
IL-1β, IL-6, eotaxin, eotaxin-3 and macrophage inflammatory protein (MIP)-1β were 
quantified in CSF using multiplex sandwich enzyme-linked immunosorbent assays 
(ELISAs) with electrochemoluminescence in the quantifying step. We employed 
MesoScale Discovery assays (MesoScale, Gaithersburg, Maryland) as per the 
manufacturer´s protocol. CSF samples were analyzed on a SECTOR 6000 instrument 
(www.mesoscale.com). The respective detection limits in our analysis were IL-6: 0.1 
pg/mL; IL-1β: 0.2 pg/mL; eotaxin, eotaxin-3 and MIP-1β. The cytokine analyses were 
undertaken in 2008, 10 ± 5 (mean ± SD) years after lumbar puncture. 
  
3.10 Statistical analysis 
 
3.10.1 Electrophysiology 
All data are expressed as mean ± SEM. Statistically significant differences regarding 
firing rate were established using Kruskal-Wallis analysis of variance followed by 
Mann-Whitney U-test. In experiments in paper III, the analysis of variance was 
followed by Mann-Whitney U-test with Bonferroni correction. Differences in percent 
spikes fired in bursts were established using Kruskal-Wallis analysis of variance 
followed by Mann-Whitney U-test or Wilcoxon signed rank test. Significance was 
assumed for all values where p < 0.05. 
 
3.10.2 Prepulse inhibition 
For each pulse-alone and prepulse-pulse trial, the startle response to the 120-dB burst 
was recorded. Two measures were then calculated from these data for each animal. 
First, startle magnitudes were calculated as the average response to the pulse-alone 
trials within each of the four blocks and analyzed with mixed-design analyses of 
variance (ANOVAs), with block as the repeated measure and pretreatment and/or 
treatment as between-subject factors. Data from the first and last blocks of five pulse-
alone trials are not presented, since the startle data from the middle two blocks when 
PPI was assessed were representative of the treatment effects, and no reliable effects on 
startle habituation were observed. Second, the amount of PPI was calculated as a 
percentage score for each prepulse + pulse trial type: %PPI = 100 - ([(startle response 
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for prepulse + pulse trial) / (startle response for pulse-alone trial)] x 100). All data were 
first analyzed in a three-factor ANOVA with blocks (first and second halves of the 
session) and prepulse as within subject factors and treatment as a between subject 
factor. When the block factor did not interact with another factor, only the two-factor 
ANOVA (treatment and prepulse intensity) are reported. The main effect of prepulse 
intensity was always significant and is not reported specifically. Post hoc comparisons 
of means were carried out with Tukey’s test. Each experiment was analyzed separately. 
All data are presented as mean ±SEM. Significance was assumed for all values where p 
< 0.05. 
 
3.10.3 Human cerebrospinal fluid studies 
Paper V: The Statistical Package for the Social Sciences (SPSS) program version 15.00 
for Windows was used. For non-normally distributed variables, values were 
transformed into natural logarithms (ln) before analysis. Linear regression correcting 
for age was used to identify significant predictors of kynurenic acid levels. We used 
Pearson´s R correcting for age (partial correlation) for correlation analyses. The 
cytokines and chemokines were measured in duplicates and the mean value was used 
for all analyses.  
 
Paper IV: Statistical analyses were performed using GraphPad Prism® 4.0b (GraphPad 
Software Inc., San Diego, CA, USA). Differences regarding CSF concentrations were 
established using Kruskal-Wallis analysis of variance followed by Mann–Whitney U-
test. Significance was assumed for all values where p < 0.05. 
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4 RESULTS AND DISCUSSION 
 
4.1 Studying the mode of action of kynurenic acid – effects of 
pharmacologically elevated endogenous levels on midbrain dopamine 
neuron firing and prepulse inhibition (paper I and II) 
As previously described (see 1.1.3), kynurenic acid is able to interact with several 
receptors. Among these, the compound antagonizes ionotropic glutamate receptors with 
a preferential selectivity at the glycine site of the NMDA receptor (IC50 ~8-15 µM; 
Parsons et al., 1997). In similar concentrations (IC50 ~7 µM; Hilmas et al., 2001) also 
the α7*nACh receptor is blocked. At higher concentrations the compound acts as a 
competitive antagonist at the glutamate recognition site of the NMDA receptor (IC50 = 
200-500 µM; Kessler et al., 1989). In paper I and II, we have focused on the receptor-
blocking effect of kynurenic acid at these sites, with regard to neurotransmission of 
glutamate and dopamine in the brain and possible involvement of the compound in 
psychiatric disorders. 
 
Previous studies have shown that acute and chronic pharmacological elevation of brain 
kynurenic acid is associated with increased firing of rat midbrain dopamine neurons 
and disruption of PPI in the rat (Erhardt et al., 2001b, 2004; Nilsson et al., 2006; Olsson 
et al., 2009). Thus, elevated levels of endogenous brain kynurenic acid are associated 
with increased firing rate and burst firing activity of rat VTA dopamine neurons 
(Erhardt et al., 2001b; Erhardt and Engberg, 2002; Nilsson et al., 2006; Schwieler et al., 
2006). Accordingly, lowering of kynurenic acid brain concentration decreases firing 
rate and burst firing activity of VTA dopamine neurons, indicating a tonic modulatory 
control of these neurons by kynurenic acid (Schwieler et al., 2006). A previous study 
(Erhardt and Engberg, 2002) suggest that the activation of midbrain dopamine neurons 
by pharmacologically elevated levels of endogenous kynurenic acid (by the 
kynurenine-3-hydroxylase inhibitor PNU 156561A) is executed via blockade of the 
glycine site of the NMDA receptor since the action of kynurenic acid is reversed by D-
cycloserine. Furthermore, recent studies have shown that local administration of 
kynurenic acid in the rat striatum produces a decrease in terminal dopamine release via 
specific blockade of α7*nACh receptors (Rassoulpour et al., 2005).  
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Study I and II aimed at verifying that the activation of midbrain dopamine neurons is 
executed via the glycine site of the NMDA receptor and furthermore to analyze the 
specific receptor involved in the ability of kynurenic acid to reduce PPI. For this 
purpose we administered drugs selectively blocking the different receptor-sites known 
to be blocked by kynurenic acid; Methyllycaconitine (MLA), a selective antagonist at 
the α7*nACh receptor; SDZ 220-581, a selective blocker of the glutamate recognition 
site of the NMDA receptor; 4-Cl-KYN, which in situ is transformed to 7-Cl-KYNA 
(Hokari et al., 1996), a highly selective antagonist at the glycine site of the NMDA 
receptor (Kleckner and Dingledine, 1989), was given to selectively block the glycine 
site of the NMDA receptor. In paper II also the effects on PPI following administration 
of CGS 19755, a selective blocker of the glutamate recognition site of the NMDA 
receptor or L-701,324, a selective blocker of the NMDA glycine site, were analyzed. 
 
4.1.1 Effects on midbrain dopamine cell firing following selective blockade of 
receptors known to be antagonized by kynurenic acid (paper I)  
Study I describes a series of electrophysiological experiments aiming to reveal the 
specific receptor involved in the excitation of VTA dopamine neurons following 
pharmacologically elevated levels of endogenous kynurenic acid. Thus, dopaminergic 
response following administration of antagonists at different kynurenic acid-inhibiting 
sites was explored. In particular, the effects of 4-Cl-KYN, MLA and SDZ 220-581 
were analyzed with regard to firing rate and burst firing activity of VTA dopamine 
neurons.  
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Utilizing microdialysis techniques, concentrations of in situ-produced kynurenic acid 
and 7-Cl-KYNA were measured in nucleus accumbens after systemic administration of 
kynurenine (200 mg/kg, s.c., n = 10) or 4-Cl-KYN (25 mg/kg, s.c., n = 6; fig. 4). Based 
on their respective time-response curve, firing of VTA dopamine neurons were 
monitored 1 – 3.5 h after administration of kynurenine (200 mg/kg, i.p., 60 neurons in 9 
rats) or 4-Cl-KYN (25 mg/kg, i.p., 105 neurons in 8 rats) and compared to the 
dopamine firing observed in saline treated controls (71 neurons in 13 rats). 
 
Systemic administration of kynurenine is associated with an increase in firing rate and 
burst firing activity of VTA dopamine neurons. Furthermore, it is associated with an 
almost two-fold increase in the number of dopamine neurons detected per track, 
indicating that elevated brain kynurenic acid concentrations increased the number of 
spontaneously active dopamine neurons. Also, the excitatory effects on VTA dopamine 
neurons observed in rats with pharmacologically elevated levels of endogenous 
kynurenic acid were mimicked by pretreatment with 4-Cl-KYN, which in situ is 
transformed to 7-Cl-KYNA, a selective antagonist at the glycine site of the NMDA 
receptor (table 1).  
 
Table 1. Firing rate and spike distribution of dopamine neurons in the VTA following intravenous 
pretreatment (1-3.5 h) with kynurenine (200 mg/kg, i.p.) or 4-Cl-Kyn (25 mg/kg, i.p.). 
 
 
 Controls   kynurenine   4-chlorokynurenine 
 (71 neurons)    (60 neurons) (105 neurons) 
 
 
Firing rate, Hz 4.0 ±0.2   5.0 ±0.2**   5.1 ±0.2**  
Mean % spikes in burst 26.7 ±2.8   40.2 ±4.0++   43.1 ±3.0+++ 
Cells found per track 1.5 ±0.2   2.1 ±0.2    2.8 ±0.4* 
 
 
Values represent means ± SEM from control rats (n=13) and rats treated with kynurenine (n=9) or 4-
Cl-KYN (n=8). *P<0.05, **P<0.01 vs. corresponding control value (Mann-Whitney U-test). ++ P<0.01, 
+++ P<0.001 vs. corresponding control value (Wilcoxon signed rank test).  
 
Our results are in consonance with previous electrophysiological studies showing that 
pharmacologically elevated levels of endogenous brain kynurenic acid are associated 
with increase in firing of midbrain dopamine neurons (Erhardt et al., 2001a; Erhardt 
and Engberg, 2002; Nilsson et al., 2006; Schwieler et al., 2006; Olsson et al., 2009) and 
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that blockade of the glycine site of the NMDA receptor per se could induce this effect. 
Furthermore, administration of SDZ 220-581 (n = 7; 10 mg/kg, i.v.), a selective and 
centrally active competitive NMDA receptor antagonist at the glutamate recognition 
site (Urwyler et al., 1996a, b), was associated with an increase in firing rate and burst 
firing activity of VTA dopamine neurons. However, the effect was typically not 
observed until 5 min after administration and also not seen following administration of 
the drug in a lower dose (5 mg/kg, i.v.). These discrepancies might be explained in 
terms of potency or problems of the drug crossing the blood-brain barrier.  
 
The excitatory actions on VTA dopamine neurons by pharmacologically elevated levels 
of endogenous kynurenic acid are thus in accordance with the effects on these neurons 
by non-competitive NMDA receptor antagonists, i.e. PCP, MK 801 (French et al., 
1991, 1993; Zhang et al., 1992), as well as by antagonists of the glycine site of the 
NMDA receptor, i.e. L-701,324 (Schwieler et al., 2004). Notably, kynurenic acid 
blocks the glutamate recognition site of the NMDA receptor although the IC50 value of 
kynurenic acid for this site is considerably higher than that of the glycine site of the 
NMDA receptor. Thus, the possibility that blockade of also glutamate recognition site 
may contribute to the observed excitation of VTA dopamine neurons by 
pharmacologically elevated levels of endogenous kynurenic acid cannot be disregarded. 
 
Intravenous administration of MLA, an α7*nACh receptor antagonist (0.5-4 mg/kg, n 
= 6-12) failed to alter firing rate or burst firing activity of VTA dopamine neurons. 
However, when the drug was injected i.p. in a relatively high dose (6 mg/kg, n = 12), a 
significant decrease in firing was observed. The effects on VTA dopamine firing 
following low doses (0.5-4 mg/kg) of MLA on VTA dopamine neurons are in line with 
a previous study (Wang et al., 2006). Furthermore, the significant decrease in firing by 
a high dose of MLA (6 mg/kg), are in consonance with the increased firing activity 
observed following administration of galantamine, an α7*nACh receptor agonist 
(Schilström et al., 2007). 
 
Altogether, present results suggest that the excitatory effect on VTA dopamine neurons 
by pharmacologically elevated levels of endogenous kynurenic acid in the brain is 
mediated via blockade of the NMDA receptor. 
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4.1.2  Effects on prepulse inhibition following selective blockade of receptors known 
to be antagonized by kynurenic acid (paper II) 
PPI is a behavioral model for sensorimotor gating which is found to be reduced in 
schizophrenia. Disruption of sensorimotor gating is considered to reflect dysfunctions 
in the ability to filter out extraneous stimuli that might interfere with information 
processing and attention. Interestingly, non-competetive NMDA receptor antagonists, 
e.g. PCP, ketamine or MK 801, disrupt PPI in rodents. These effects on PPI are also in 
line with the NMDA receptor hypofunction hypothesis of schizophrenia, based on the 
finding that NMDA receptor antagonists cause psychotic symptoms in healthy 
volunteers and exacerbate clinical symptoms in patients with schizophrenia. In line 
with these findings, a previous study has also shown that pharmacologically elevated 
levels of endogenous kynurenic acid disrupt PPI in the rat. However, the specific 
receptor mechanism involved was not ascertained even though it is suggested to be 
mediated, at least partly, via blockade of the glutamate recognition site of the NMDA 
receptor (Erhardt et al., 2004). In paper II, we investigated which receptor(s) mediate 
the effects of pharmacologically elevated levels of endogenous kynurenic acid on PPI. 
For this purpose we administered drugs selectively blocking the receptors known to be 
blocked by kynurenic acid; MLA, a selective α7*nACh receptor antagonist; SDZ 220-
581 and CGS 19755, selective blockers of the glutamate recognition site of the NMDA 
receptor; L-701,324 and 4-Cl-KYN, in situ converted to 7-Cl-KYNA, was given to 
selectively block the glycine site of the NMDA receptor. 
 
The results of this study show that rats administered kynurenine (200 mg/kg) displayed 
a five-fold increase in whole brain kynurenic acid levels (123.1 nM ± 18.8, n = 14) 
compared to controls 23.3 nM ± 2.7, n = 13). This increase was associated with a 
tendency to disrupt PPI (F(1,25) = 2.56, p = 0.12: fig. 5). Treatment with drugs 
blocking the glutamate recognition site of the NMDA receptor, i.e. SDZ 220-581 (2.5 
mg/kg; n = 12; F(1,22)=12.33, p < 0.01) or CGS 19755 (10 mg/kg; n = 12; 
F(1,22)=16.47, p < 0.001), was found to clearly reduce PPI (fig. 6) and our results thus 
confirm that blockade of the glutamate recognition site of the NMDA receptor is 
associated with a disrupted PPI (Bakshi et al., 1999; Depoortere et al., 1999). In 
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contrast, blockade of either the α7*nACh receptor with MLA (6 mg/kg; n = 15); the 
NMDA glycine site with L-701,324 (1 mg/kg; n = 13; or 4 mg/kg; n = 17) or 4-Cl-
KYN (25; 50 or 100 mg/kg; n = 15, n = 14 and n = 10, respectively) failed to reduce 
PPI. The effects of L-701,324 and 4-Cl-KYN are in line with previous studies showing 
that systemic administration of antagonists of the NMDA glycine site does not affect 
PPI (Depoortere et al., 1999; Bristow et al., 1995). However, 7-Cl-KYNA when locally 
injected intracerebroventricularly (i.c.v.), or into the nucleus accumbens, has been 
found to reduce PPI (Furuya et al., 1997; Kretschmer et al., 1997, 1998). A benefit of 
using systemic administration of 4-Cl-KYN is the in situ production of 7-Cl-KYNA. 
Hence, 4-Cl-KYN utilizes the same enzymatic machinery as kynurenine and hence 7-
Cl-KYNA will be produced in the same regions and micro-compartments as kynurenic 
acid is produced. Thus, the absence of an effect on PPI following pretreatment of 4-Cl-
KYN reliably suggests that the glycine site of the NMDA receptor is not primarily 
involved in the modulation of PPI. Furthermore, the tendency toward an increased PPI 
in this study following administration of MLA, is consistent with a previous study by 
Schreiber et al (2002), and by the finding that PPI is normal in α7* null mutant mice 
(Paylor et al., 1998). The results of the present study is however, not in line with other 
reports, as it has been shown that administration of α-bungarotoxin, another α7*nACh 
receptor antagonist, or removal of hippocampal cholinergic afferents, actually disrupts 
PPI (Bickford et al., 1995; Luntz-Leybman et al., 1992; Stevens, et al., 2001).  
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Altogether, the results suggests that neither antagonism of the glycine site of the 
NMDA receptor nor antagonism of the α7*nACh receptor is associated with the ability 
of kynurenic acid to disrupt PPI. Rather, with regard to the effects of kynurenic acid, 
blockade of the glutamate recognition site is necessary to reduce PPI. 
 
4.2 Altered levels of kynurenic acid change the response of clozapine on 
midbrain dopamine neuron firing (paper III) 
Previous electrophysiological studies show that all antipsychotic drugs, including 
clozapine, when acutely administered increase the firing rate and burst firing activity of 
VTA dopamine neurons (Gessa et al, 2000; Tung et al, 1991; White and Wang, 1983). 
However, previous studies show that the response of VTA dopamine neurons is 
changed from an excitatory action in control rats to a pure inhibitory response in rats 
with pharmacologically elevated levels of brain kynurenic acid (Schwieler and Erhardt, 
2003; Schwieler et al., 2004). Furthermore, in vivo electrophysiological experiments 
have shown a modulatory role of endogenous kynurenic acid in regulating neuronal 
activity of VTA dopamine firing. Thus, pharmacological elevation of endogenous brain 
kynurenic acid levels is associated with increased firing rate and burst firing activity of 
rat midbrain dopamine neurons (Erhardt et al., 2001a; Erhardt and Engberg, 2002; 
Nilsson et al., 2006; Schwieler et al., 2006; Olsson et al., 2009). Accordingly, lowering 
of endogenous brain kynurenic acid concentration decreases firing rate and burst firing 
activity of VTA dopamine neurons, demonstrating a tonic modulatory control of these 
neurons by kynurenic acid (Schwieler et al., 2006). In the present study the response to 
clozapine on firing activity of VTA dopamine neurons was investigated in rats with 
increased or decreased levels of endogenous brain kynurenic acid. Rat brain kynurenic 
acid concentrations were pharmacologically manipulated by administration of a 
preferential cyclooxygenase 1 (COX-1) inhibitor (indomethacin) or a selective COX-2 
inhibitor (parecoxib), drugs previously shown to increase or decrease brain kynurenic 
acid, respectively (Schwieler et al., 2005, 2006).  
 
Present results show that in control rats, intravenous administration of clozapine 
(0.078-10 mg/kg, n = 7) produced a dose-dependent increase in firing activity (fig. 7) 
and in percent spikes fired within bursts, in line with previous studies (White and 
Wang, 1983; Tung et al., 1991; Gessa et al., 2000; Schwieler and Erhardt, 2003; 
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Schwieler et al., 2004). Furthermore, our results confirm that pretreatment with 
indomethacin (50 mg/kg, i.p., n = 9) or parecoxib (25 mg/kg, i.v., n = 12), increase or 
decrease endogenous levels of kynurenic acid, respectively (253% and 48% of brain 
kynurenic acid levels detected in controls). In line with a previous study (Schwieler et 
al., 2006), the elevated or lowered kynurenic acid concentration was associated with 
increased or decreased VTA dopamine firing activity, respectively. Moreover, the 
elevated brain kynurenic acid levels converted the excitatory effects of clozapine into a 
pure inhibitory response (fig. 7). In contrast, the reduction in brain kynurenic acid 
concentration by parecoxib clearly potentiated the excitatory actions of clozapine; i.e. 
considerably lower doses were required to produce a significant increase in firing 
activity (fig. 7). 
 
Present results are in line with previous studies showing that elevated brain levels of 
kynurenic acid or systemic administration of a selective NMDA glycine site antagonist, 
i.e. L-701,324, reverses the excitatory actions of clozapine into an inhibitory response 
(Schwieler and Erhardt, 2003; Schwieler et al., 2004). Notably, a clear-cut inhibitory 
effect of clozapine is observed already at a dose of 1.25 mg/kg. Such doses in rats 
correspond with clinically therapeutic doses according to brain imaging studies in 
humans (Nordström et al., 1993a, 1993b; Schotte et al., 1996; Farde et al., 1997). This 
is of particular interest since this dose did not produce a significant activation of VTA 
dopamine neurons in control rats but clearly inhibited the same neurons in a situation 
where endogenous brain kynurenic acid was elevated. The activation of midbrain 
dopamine neurons by antipsychotics, including clozapine, has generally been attributed 
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to a blockade of somatodendritic dopamine D2 receptors (Pucak and Grace, 1996; 
Gessa et al., 2000). However, clozapine displays a weak dopamine D2-receptor 
occupancy (Mukherjee et al., 2001) and other dopamine antagonists, e.g. haloperidol or 
sulpiride, do not affect midbrain dopamine firing in doses equipotent to those of 
clozapine with regard to dopamine D2-receptor occupancy (Pucak and Grace, 1996; 
Schwieler and Erhardt, 2003). Thus, antagonism of somatodendritic dopamine D2 
receptors by clozapine should not solely account for the activation of VTA dopamine 
neurons. Rather, the presently observed interaction of endogenous kynurenic acid with 
clozapine strongly suggests that the activation of VTA dopamine neurons by the drug 
involves an action on glutamatergic neurotransmission. Thus, clozapine has been 
shown to modulate the response of NMDA in frontal cortex slices in vitro (Arvanov et 
al.,1997; Chen and Yang, 2002; Jardemark et al., 2003) and to prevent NMDA receptor 
hyperactivity seen after repeated PCP treatment in vivo (Arvanov and Wang, 1999). 
Further, clozapine has been found to inhibit the System A transport which, together 
with glycine transporters, is responsible for homeostasis of glycine (Javitt et al., 2005). 
Studies from our laboratory also point to a direct interaction between clozapine and the 
glycine site of the NMDA receptor (Schwieler and Erhardt, 2003; Schwieler et al., 
2004). Indeed, the activation of VTA dopamine neurons by clozapine resembles that 
observed by i.v. administration of L-701,324 (Schwieler et al., 2004) or by elevated 
endogenous levels of kynurenic acid (Erhardt and Engberg, 2002). These actions are 
thought to be induced by blockade of the glycine site of the NMDA receptor on 
inhibitory γ-aminobutyric acid (GABA) afferents controlling activity of midbrain 
dopamine neurons. The enhanced response of VTA dopamine neurons to clozapine 
seen following lowered kynurenic acid is what should be expected from a partial 
NMDA glycine site agonist (Tsai et al., 1999; Coyle and Tsai, 2004). Thus, under a 
condition where the NMDA glycine site may be saturated by the endogenous ligands 
(glycine or D-serine) an antagonistic action of clozapine would prevail leading to 
increased firing activity. In contrast, when a high degree of blockade of the NMDA 
glycine site is present (due to elevated kynurenic acid concentration) an agonistic action 
of clozapine would be more prominent, hereby decreasing impulse activity. Thus, 
clozapine appears to stabilize dopamine neurons, dampening both hyper- and 
hypoactivity via an agonistic and antagonistic action at the NMDA glycine site, 
respectively. Such an effect of clozapine is also proposed to occur with respect to 
prefrontal cortex neurons (Homayoun and Moghaddam, 2007). Indeed, the presently 
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revealed effects of clozapine on VTA dopamine neurons bear a striking similarity to the 
actions on these neurons by systemic administration of D-cycloserine, a partial 
NMDA/glycine site agonist. Thus, administration of D-cycloserine increases VTA 
dopamine firing in control rats and decreases firing in rats with elevated brain levels of 
kynurenic acid (Erhardt and Engberg, 2002). A partial agonistic action at the NMDA 
glycine site of clozapine is also supported by clinical data. Thus, D-cycloserine in 
combination with traditional or second generation antipsychotics improves symptoms 
of schizophrenia. A unique interaction between clozapine and the glycine site of the 
NMDA receptor might explain the paradoxical worsening in negative symptoms when 
D-cycloserine is added to clozapine in patients with schizophrenia (Goff et al., 1999). 
 
4.3 Kynurenic acid in human cerebrospinal fluid from patients with 
psychiatric disorders (paper IV and V) 
Previous studies have shown that kynurenic acid is elevated in the CSF and in the post 
mortem brain of patients with schizophrenia (Erhardt et al., 2001a, Schwarcz et al., 
2001, Nilsson et al., 2005). Furthermore, a recent study also showed increased levels of 
kynurenic acid in the CSF from patients with bipolar disorder (Olsson et al., 2010) and 
an up-regulated kynurenine pathway has been associated with depression (Myint et al., 
2007; Wichers et al., 2005; Wichers and Maes, 2004; Raison et al., 2009). An increased 
synthesis of kynurenic acid might result from an induction of IDO and/or TDO, 
enzymes responsible for the rate-limiting step of the kynurenine pathway. Notably, 
these enzymes are induced during infections or immune-activation (Asp et al., 2009; 
Holtze et al., 2008; Schmidt et al., 2009) and numerous studies suggest that kynurenic 
acid is a biological marker of neuroinflammation (Dantzer et al., 2008; King et al., 
2008). Increasing evidence also suggests that immunological processes are involved in 
the etiology of depression (Charlton, 2000; Hart, 1988; Dantzer et al., 1989) and a 
recent study show increased concentration of the pro-inflammatory cytokine 
interleukin-1β in first-episode patients with schizophrenia (Söderlund et al., 2009). 
Thus, in paper IV we investigate levels of key metabolites in the kynurenine pathway in 
the CSF of patients with schizophrenia and in paper V levels of kynurenic acid were 
measured in suicide attempters and compared to inflammatory markers and diagnostic 
groups. 
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4.3.1  Analysis of kynurenic acid and its precursors kynurenine and tryptophan in 
the cerebrospinal fluid of patients with schizophrenia (paper IV) 
Kynurenic acid has an exceptional receptor binding profile as it blocks both 
glutamatergic and cholinergic receptors. This is particularly interesting in 
schizophrenia, given that hypoglutamatergia, possibly induced by NMDA receptor 
hypofunction, is widely accepted as part of the pathophysiology. In addition, the 
importance of an intact α7*nACh receptor signaling in cognitive functions has been 
suggested in numerous studies over the last decade (Albuquerque et al., 2009). In 
further support of the kynurenic acid hypothesis of schizophrenia are studies showing 
that pharmacologically elevated levels of kynurenic acid disrupt cognitive functions 
such as sensory motor gating, contextual learning and working memory (Erhardt et al., 
2004, Chess and Bucci 2006, Chess et al 2007; 2009), domains to a large extent 
affected in patients with schizophrenia. 
 
 
 
In the present study, kynurenic acid and its precursors kynurenine and tryptophan were 
measured in the CSF of male (n = 16) and female patients (n = 8) with schizophrenia 
and in a group of healthy male (n = 29) and female (15) volunteers. All patients were 
prescribed and taking the antipsychotic drug olanzapine at the time of lumbar puncture. 
The results show that CSF kynurenic acid is elevated (p < 0.01) in patients with 
schizophrenia (1.97 nM ± 0.17, n = 24; fig. 8) compared to healthy volunteers (1.42 nM 
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± 0.08, n = 44). Furthermore, we found elevated levels (p < 0.001) of kynurenine, the 
immediate kynurenic acid precursor (59.9 nM ± 3.60, n = 24; fig. 8), but not of 
tryptophan (1.75 µM ± 0.04, n = 24; fig. 8), in the CSF of patients with schizophrenia 
compared to healthy volunteers (37.2 nM ± 2.77, 1.78 µM ± 0.05, respectively, n = 44). 
When analyzed with regard to gender, we were able to confirm increased levels (p < 
0.01) of CSF kynurenic acid in male patients with schizophrenia (2.03 nM ± 0.23 vs. 
1.36 nM ± 0.08 in healthy male volunteers). Additionally, we here report increased 
levels (p < 0.001) of kynurenine in male patients with schizophrenia (60.7 nM ± 4.37 
vs. 28.6 nM ± 1.44 in healthy male volunteers). Levels of CSF tryptophan in male 
patients with schizophrenia were found to be within the same range as in healthy male 
volunteers. In a smaller cohort of female patients with schizophrenia (n = 8), levels of 
kynurenic acid, kynurenine and tryptophan were unchanged compared to healthy 
female volunteers (n = 15). Present results are thus in line with previous studies 
showing increased CSF kynurenic acid in first-episode, drug-naive patients or patients 
receiving various antipsychotic treatments (Erhardt et al., 2001a; Nilsson et al., 2005), 
further supporting a role of kynurenic acid of in the pathophysiology of schizophrenia. 
The cause of the difference between male and female patients is unclear, however this 
may be related to the relatively low number of female patients and volunteers analyzed.  
 
Kynurenine was markedly elevated in male patients with schizophrenia. This is a novel 
finding in line with previous post mortem studies (Miller et al., 2006; 2008) further 
supporting an induction of the kynurenine pathway in schizophrenia. The elevated CSF 
kynurenine levels may arise from an increased synthesis of kynurenine from 
tryptophan, or alternatively, a decreased synthesis of 3-hydroxykynurenine from 
kynurenine. An increased synthesis of kynurenine might result from an induction of 
IDO/TDO, enzymes responsible for the rate-limiting step of the kynurenine pathway. 
These enzymes are induced during infections or immune-activation (Schmidt et al., 
2009; Asp et al., 2009; Holtze et al., 2008) and gene expression of TDO is found to be 
elevated in post mortem brain of patients with schizophrenia (Miller et al., 2004). 
Alternatively, a decreased synthesis of 3-hydroxykynurenine from kynurenine, 
resulting in increased kynurenine levels, is supported by experimental as well as 
genetic studies (Speciale et al., 1996; Erhardt et al., 2000; Erhardt and Engberg 2000; 
Schwieler and Erhardt, 2003; Rassoulpour et al., 2005; Sathyasaikumar et al., 2009; 
Holtze et al., 2010). In conclusion, present results confirm increased levels of kynurenic 
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acid, and additionally, we found increased levels of kynurenine, in the CSF of patients 
with schizophrenia. 
 
4.3.2  Kynurenic acid in the cerebrospinal fluid of male suicide attempters (paper V) 
A recent study shows increased levels of IL-6 in the CSF of suicide attempters and the 
highest levels were found in patients who performed violent suicide attempts and/or 
had a diagnosis of MDD (Lindqvist et al., 2009). In this study, CSF concentration of 
kynurenic acid and the correlation to CSF levels of pro-inflammatory cytokines and 
chemokines were analyzed in 54 male suicide attempters and 66 healthy male 
volunteers. The suicide attempters with well-defined clinical psychiatric profiles were 
lumbar punctured after a drug wash-out period of approximately 2 weeks after the 
suicide attempt. CSF kynurenic acid concentrations displayed a skewness above 2 in all 
120 subjects and all values were subsequently transformed into normal distribution, 
using their natural logaritms, which were used for all calculations. Also, CSF kynurenic 
acid levels were adjusted for age in all analyses. The results show that a violent suicide 
attempt predicts a significantly increased kynurenic acid level (1.80 nM ± 0.37, n = 20; 
p < 0.05; fig. 9) compared to healthy volunteers (1.14 nM ± 0.06, n = 66). Moreover, a 
diagnosis of MDD (n = 14) is clearly associated with increased CSF kynurenic acid 
levels (1.93 nM ± 0.46, p = 0.013; fig. 9) whereas a diagnosis of substance abuse (n = 
15) is associated with lower levels of CSF kynurenic acid (0.95 nM ± 0.19; p < 0.05). 
In all subjects, MIP-1β was significantly correlated with kynurenic acid, and in healthy 
controls, a correlation was found between CSF kynurenic acid and eotaxin-3.  
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Furthermore, a trend towards a correlation (p = 0.08) between ln-IL-6 and ln-kynurenic 
acid was observed in a smaller cohort of patients (n = 33), indicating that the elevated 
CSF kynurenic acid levels in patients with MDD might causally be related to the 
increased levels of IL-6 (Lindqvist et al. 2009).  
 
Taken together, present results support the notion that immune activation is associated 
with increased levels of kynurenic acid. Thus, cytokine-induced induction of IDO/TDO 
resulting in elevated brain levels of kynurenic acid might be a potential mechanism by 
which the immune system contributes to the development of psychiatric disorders and 
manifestations of psychiatric symptoms.  
 
In conclusion, the present study demonstrates that immunologically active compounds, 
e.g. kynurenic acid and IL-6, are elevated in the CSF of violent suicide attempters and 
especially in those patients suffering from MDD, whereas a diagnosis of substance 
abuse is associated with lower levels of CSF kynurenic acid.  
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5 GENERAL DISCUSSION 
 
The physiological role of kynurenic acid has been questioned ever since its presence 
was first discovered in the human brain (Moroni et al., 1988; Turski et al., 1988). Thus, 
the concentration of the compound found in human post mortem and CSF studies or in 
animal whole brain and extracellular fluid is below that required to affect either the 
NMDA glycine site (IC50 = 8-15 µM; Parsons et al., 1997) or the α7*nACh receptor 
(IC50 = 7 µM; Hilmas et al., 2001). However, a variety of animal studies have clearly 
confirmed that very low, i.e. nM concentrations, of kynurenic acid play an important 
physiological role in the brain (Amori et al., 2009; Rassoulpour et al., 2005; Sapko et 
al., 2006; Shephard et al., 2003; Wu et al., 2009). Furthermore, pharmacologically 
elevated levels of kynurenic acid increase midbrain dopamine firing (Erhardt et al., 
2001b; Erhardt and Engberg 2002; Nilsson et al., 2006; Schwieler et al., 2006; 2008; 
Linderholm et al., 2007; Olsson et al., 2009) whereas lowered levels of kynurenic acid 
dampen the activity of these neurons (Schwieler et al., 2006; 2008). The discrepancy 
between in vivo and in vitro studies might be related to the production and release of 
kynurenic acid by astrocytes, known to be closely connected to the synapse and there 
adjoining glutamatergic boutons (Araque et al., 1999). Such an appropriate location 
puts the newly produced kynurenic acid in an excellent position to interact with 
glutamatergic and cholinergic receptors. Thus, although the levels of CSF kynurenic 
acid found in the patients with schizophrenia and the suicide attempters in the present 
thesis are relatively low, the real concentration at critical sites of action, i.e. within the 
synapses, should be sufficient to interact with glutamatergic/cholinergic receptors. 
Interestingly, both NMDA receptor and α7*nACh receptor hypofunctions are 
suggested to be widely implicated in the pathophysiology of psychiatric disorders 
(Javitt, 2007; Albuquerque et al., 2009). Besides elevated levels of kynurenic acid in 
patients with schizophrenia (Erhardt et al., 2001a; Schwarcz et al., 2001; Nilsson et al., 
2005; present thesis), patients with bipolar disorder also display elevated CSF 
kynurenic acid levels (Olsson et al., 2010). Interestingly, animal studies point to a close 
relationship between kynurenic acid and cognitive functions and it is thus tempting to 
speculate that dysfunctions in cognitive domains, which are common in almost all 
psychiatric disorders, is related to elevated brain levels of kynurenic acid (Wonodi and 
Schwarcz, 2010).  
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Although the physiological significance of brain kynurenic acid has been demonstrated 
in a number of studies during the last decade (see Erhardt et al., 2009), it is unclear 
what type of receptor(s) participate in the various effects of kynurenic acid in the brain. 
A previous study suggests that the increased firing of rat midbrain dopamine neurons 
following pharmacological elevation of brain kynurenic acid is mediated via blockade 
of the glycine site of the NMDA receptor (Erhardt and Engberg 2002). However, local 
administration of kynurenic acid in the rat striatum decreases terminal dopamine 
release via specific blockade of α7*nACh receptors (Rassoulpour et al., 2005). In 
addition, a previous study has suggested that blockade of the glutamate recognition site 
is responsible for the disrupted PPI following pharmacologically elevated levels of 
kynurenic acid in the rat (Erhardt et al., 2004). In the present thesis, we show that 7-Cl-
KYNA, a selective antagonist at the glycine site of the NMDA without blocking the 
glutamate recognition site or the α7*nACh receptor, produces the same magnitude of 
response with regard to firing of VTA dopamine neurons as kynurenic acid at 
equipotent concentrations. This finding provides strong evidence that kynurenic acid 
increases VTA dopamine firing by blocking the glycine site of the NMDA receptor. 
The excitatory action on VTA dopamine neurons by SDZ 220-581, a competitive 
antagonist at the glutamate recognition site of the NMDA receptor, principally indicates 
that the ability of kynurenic acid to block also this site could participate in its excitatory 
effects on VTA dopamine neurons, although relatively high concentrations of 
endogenous brain KYNA would be required. Blockade of the α7*nACh receptor, by 
MLA in high dose, were associated with a reduced firing of the VTA dopamine 
neurons. This finding is in line with the excitatory action of galantamine, an α7*nACh 
receptor agonist (Schilström et al., 2007) on VTA dopamine neurons, making it 
unlikely that blockade of the α7*nACh receptor contributes to the increased firing of 
VTA dopamine neurons following elevated levels of kynurenic acid. The present thesis 
also suggests that neither antagonism of the glycine site of the NMDA receptor nor 
antagonism of the αα7*nACh receptor disrupt PPI. Rather, with regard to the effects of 
kynurenic acid, blockade of the glutamate recognition site is necessary to reduce PPI. 
 
Although the present thesis reveals that blockade of the NMDA receptor accounts for 
the excitatory action on VTA dopamine neurons as well as the disrupted PPI by 
elevated levels of endogenous kynurenic acid, the antagonizing action at the 
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αα7*nACh receptor by kynurenic acid should not be disregarded, especially with 
respect to the functional effects in other brain areas, e.g. on striatal dopamine release 
(Rassoulpour et al., 2005). Indeed, in recent years it has been suggested that symptoms 
of schizophrenia might be attenuated by administration of drugs activating the glycine 
site of the NMDA receptor (e.g. by serine or glycine) or the αα7*nACh receptor (e.g. 
by galantamine). Given the proposed role of endogenous kynurenic acid in the 
pathophysiology of schizophrenia, the beneficial effects of such treatment might 
rationally be explained in terms of displacement of kynurenic acid at the levels of the 
NMDA receptor and/or the αα7*nACh receptor.  
 
In the present thesis we also found that the response on VTA dopamine firing by 
clozapine is dependent on brain levels of endogenous kynurenic acid. Elevation of rat 
brain levels of kynurenic acid may rationally mimic the hypoglutamatergic and 
hypocholinergic condition proposed in patients with schizophrenia (see Erhardt et al., 
2009; Wonodi and Schwarcz 2010). Notably, in such a situation, clozapine produces an 
inhibitory action on VTA dopamine neurons. This effect is probably induced via an 
agonistic action at the NMDA glycine site and is most prominent in the 
hypoglutamatergic brain. On the contrary, when the NMDA glycine site is saturated by 
endogenous ligands as a result of decreased kynurenic acid concentration, an 
antagonistic action of clozapine is associated with an activation of VTA dopamine 
neurons. This pharmacological profile, i.e. partial agonism of the glycine site of the 
NMDA receptor, may contribute to the unique efficacy of clozapine as an antipsychotic 
drug. 
 
Increasing evidence suggests that immunological processes may contribute to the 
etiology of psychiatric disorders (Dantzer, 2008; Sperner-Unterweger, 2005). Indeed, it 
was recently found that the CSF levels of IL-1β are elevated in first-episode patients 
with schizophrenia (Söderlund et al., 2009). Furthermore, elevated CSF levels of IL-6 
were recently reported in suicide attempters (Lindqvist et al., 2009). An up-regulated 
kynurenine pathway may be a consequence of an activated immune system as studies 
have shown that immunological agents induce TDO/IDO (Asp et al., 2009; Babcock 
and Carlin 2000; Guilleman et al, 2001; Holtze et al., 2008; Schmidt et al., 2009; Shirey 
et al., 2006; Takikawa et al., 1988), the rate-limiting enzymes in the production of 
kynurenic acid. Interestingly, numerous studies suggest that kynurenic acid may serve 
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as a marker of immune-activation (Eastman et al 1994; Schwarcz and Hunter 2007; 
Silva et al., 2002; Holtze et al., 2008; Asp et al., 2009). Elevation of endogenous 
kynurenic acid might thus, be a potential mechanism by which the immune system 
contributes to the development of psychiatric disorders and manifestations of 
psychiatric symptoms. This theory is supported by the close correlation between 
cytokines/chemokines and kynurenic acid in the CSF of suicide attempters observed in 
the present thesis. Indeed, kynurenic acid, with its unique receptor profile, may be the 
link between an activated immune system and the alterations in glutamatergic, 
cholinergic and dopaminergic neurotransmission proposed to occur in psychiatric 
disorders.  
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